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Between April 1993 and July 1996, two twin brothers sexually assaulted at least sixteen women
in California.1 The Spitzer brothers did not use physical force or guns or knives to commit
the rapes; instead, they used a newer type of weapon { the powerful sedative Rohypnol { to
1Sue McAllister, Jury Convicts Twin Brothers in Date Rape Drugging Case, Los Angeles Times, June 18, 1998, at
B3. Although the term \sexual assault" includes more activities than the term \rape," I use the two terms interchangeably
throughout this paper for the sake of variety.
3render their victims unconscious. Their victims included a ight attendant, a lawyer, a shoe
salesperson, a single mother, and a college student.2 The brothers followed the same plan
with each victim. One of the brothers would invite a woman to go on a date with him, and
would then slip the undetectable drug into her glass. Once the woman entered a hypnotic,
dream-like state, the brother would rape her, often lming the act to make sexual videos.3
After his arrest, Julian Spitzer's explanation for the sex tapes was that the women \were, you
know, having a good time."4 One of the victims described her last memory before she was
raped: \I felt paralysis. I couldn't move. I couldn't lift my head."5 When the victims awoke
in bed with one of the brothers, they would have no memory of what had transpired.6
At approximately the same time as the Spitzer brothers were using Rohypnol to drug and rape women, two
other Californian men chose a dierent weapon to commit similar crimes. Steven Michael Hagemann and
Danny Richard Bohannon slipped the depressant gamma-hydroxybutyrate (GHB) into the drinks of at least
ten women, and then raped and photographed their unconscious victims.7 The pair also drugged at least
six men to prevent them from protecting their female friends. Like the Spitzers, these two men claimed the
sex was consensual. One of their victims reported that she had been \shattered emotionally" and nancially
\destroyed" because she lost her job due to emotional problems after the rape.8
As early as 1985, a man in New York had discovered yet a third drug to facilitate rape. Richard Esposito
invited two women to a discotheque, and while the women danced he dropped ketamine, an animal tran-
2Julia Scheeres, Trial Oers Look at Date-Rape Drug, Los Angeles Times, May 31, 1998, at B1.
3Id.
4Id.
5Id.
6Id.
7Greg Krikorian, 2 Guilty in `Date Rape' Drug Case, Los Angeles Times, July 4, 1997, at B1.
8Greg Krikorian, 2 Sentenced in `Date Rape Drug' Attacks, Los Angeles Times, Aug. 6, 1997, at B1.
4quilizer, into their drinks.9 He took them to a motel and raped and sodomized the drugged women.10
These three cases reveal that in the last two decades, men who wish to sexually assault women11 have discov-
ered powerful new weapons to facilitate their plans. Often referred to as \date-rape drugs," Rohypnol, GHB,
and ketamine12 are used by rapists to render women unconscious, making them unable to resist unwanted
sexual advances. The American Prosecutors Research Institute denes \drug-facilitated rape" as:
[s]exual assault facilitated by the oender's use of an `anesthesia-type' drug which when
administered to the victim (stealthily or not) render[s] the victim `physically incapacitated
or helpless,' and thus incapable of giving or not giving consent. These victims are usu-
ally unconscious during their sexual assault and have anterograde amnesia upon gaining
consciousness, similar to the eects of a surgery patient coming out of anesthesia.13
Drug-facilitated rape presents its victims and law enforcement personnel with an additional set of challenges
above and beyond those associated with other sexual assaults. This paper will explore those challenges by
examining the problem of drug-facilitated sexual assault and the response to this problem.
More specically, Part I of this paper presents the problem of drug-facilitated sexual assault by describing
three of the many drugs used in such assaults and explaining the characteristics and prevalence of drug-
facilitated rape. Part II outlines the responses to the problem developed by the federal, state, and local
governments as well as by private actors. Finally, Part III examines these responses and provides recom-
mendations for additional responses to the problem of drug-facilitated sexual assault.
9137-Year Sentence in Queens, N. Y. Times, Nov. 14, 1985, at B18.
10Id.
1199 in 100 [rapists] are male... females account for a small percentage of known oenders, [and] in a very small fraction of
sexual assaults, victim and oender are of the same sex. Lawrence A. Greenfield, Bureau of Justice Statistics, U.S.
Dept. of Justice, NCJ-163392, Sex Offenses and Offenders: An Analysis of Data on Rape and Sexual Assault iii
- iv (1997). Given these facts, this paper refers to rapists as male and victims as female, although I acknowledge that these
labels may not always be accurate.
12This paper focuses only on these three drugs, although many others have been used to facilitate rape, especially alcohol
and marijuana. See American Prosecutors Research Institute, The Prosecution of Rohypnol and GHB Related
Sexual Assaults, Ch. 1, pp. 13 { 17 (1999) [hereinafter APRI] (describing twenty-one other drugs used to facilitate sexual
assault). I have chosen this focus because these three drugs have garnered the most attention from the government, media,
and medical eld. Although I later argue that this narrow focus should be avoided, I found it necessary to mirror these group's
focus in order to describe most accurately the overall response to the date rape drug crisis. It should be clear from the outset
of this paper, however, that my focus on Rohypnol, GHB, and ketamine in no way suggests that these three drugs are the most
prevalent or dangerous drugs related to rape.
5I.
The Problem of Drug-Facilitated Sexual Assault
This section describes three drugs { Rohypnol, GHB, and ketamine { that men use to commit drug-facilitated
sexual assault. It also discusses the unique characteristics and prevalence of the crime of drug-facilitated
sexual assault.
A.
The Drugs
1.
Rohypnol
Rohypnol is the brand name for unitrazepam, which is a benzodiazepine (BZ) manufactured by the Swiss-
based company Homan-La Roche, Inc.14 BZs are generally used as sleep aids, sedatives, muscle relaxants,
and to reduce seizures and produce anterograde amnesia.15 Rohypnol is a legal drug in Europe, Asia, and
Latin America, and during the mid-1990s was the most widely prescribed sedative in Western Europe.16 Its
14Drug Enforcement Administration, U.S. Department of Justice, Flunitrazepam (last modied Nov. 23, 1999)
<http://www.usdoj.gov/dea/pubs/rohypnol/rohypnol.htm>. Flunitrazepam is also marketed under the trade name Hypnodorm,
but much less frequently. Regardless of the actual manufacturer, users of unitrazepam and the media refer to the drug as
Rohypnol. This paper follows suit and also refers to unitrazepam as Rohypnol.
15National Institute of Justice, U.S. Department of Justice, A Report to the Attorney General from the Department of Justice
Drug-Facilitated Rape Working Group 12 (June 26, 1998) [hereinafter NIJ, A Report to the Attorney General]. When a person
experiences anterograde amnesia, she does not remember the events during the time in which a drug is in eect. Retrograde
amnesia, on the other hand, is a condition in which a person does not remember events prior to the intervening agent. Id. Other
benzodiazepines include Valium, Librium, Xanax, and Halcion. Drug Enforcement Administration, U.S. Department of Justice,
DEA Brieng Book (last modied Oct. 15, 2000) <http://www.usdoj.gov/dea/briengbook/page16-31.htm#rohypnol>.
16Christine A. Saum and James A. Inciardi, Rohypnol Misuse in the United States, 32 Substance Use & Misuse 723, 724
(1997).
6physiological eects are similar to those of Valium, although Rohypnol is approximately seven to ten times
more potent.17 Adverse eects of Rohypnol use include decreased blood pressure, memory impairment,
drowsiness, visual disturbances, dizziness, confusion, gastrointestinal disturbances, and urinary retention.18
High doses of Rohypnol may create respiratory depression, and chronic use may result in dependence and
withdrawal symptoms if use is discontinued.19 When mixed with alcohol and/or other drugs, Rohypnol
may cause death due to cardiovascular collapse or enhanced nervous system depression.20 The drug's most
important features for the purposes of this paper are that, like other BZs, it produces muscle relaxation and
anterograde amnesia. The sedative eects of Rohypnol normally begin to occur within thirty minutes after
ingesting the drug, peak within two hours, and may continue for eight hours or more.21 Rohypnol is sold in
tablet form, and normally ingested as a pill, although some users grind the pills into a power and snort the
drug.22
Many street names exist for Rohypnol, including Rooes, Rophies, Roche, Forget-Me-Pill, Mexican Valium,
R-2, Rib, Rope, and Roaches.23 Rohypnol is considered a \club drug," meaning it is commonly used at
nightclubs and raves.24 Several dierent groups of people use Rohypnol. In the more than seventy countries
17Drug Enforcement Administration, DEA Brieng Book, supra note 15.
18Drug Enforcement Administration, Flunitrazepam, supra note 14. See also Saum and Inciardi, supra note 16, at 725;
Sarah R. Calhoun et al., Abuse of Flunitrazepam (Rohypnol) and Other Benzodiazepines in Austin and South Texas, 28 J.
Psychoactive Drugs 183, 187 (1996).
19Drug Enforcement Administration, DEA Brieng Book, supra note 15. Withdrawal symptoms may include muscle pain,
extreme anxiety, confusion, numbness, loss of identity, hallucinations, convulsions, shock, and cardiovascular collapse. Drug
Enforcement Administration, Flunitrazepam, supra note 14.
20Saum and Inciardi, supra note 16, at 726.
21Drug Enforcement Administration, Flunitrazepam, supra note 14.
22Oce of National Drug Control Policy, Facts & Figures: Club Drugs (visited Mar. 25, 2001)
<http://www.whitehousedrugpolicy.gov/drugfact/club/index.html>.
23Id.
24See Drug Enforcement Administration, U.S. Department of Justice, An Overview of Club Drugs, Drug Intelligence
Brief 1 (Feb. 2000); see also National Institute on Drug Abuse, Department of Health and Human Services, Club Drugs Home
(visited March 25, 2001) <http://www.clubdrugs.org>. One detective describes a rave as \basically a dance party.... Very loud
music, mostly techno, lot of synthesizers, a lot of bass, colored lights, ashing lights, strobe lights. They originally started out
as spontaneous parties.... Right now the Rave is very commercialized.... They [are] all night parties, which, as far as we are
concerned at the Orlando Police Department, exist to get the drugs out." Controlled and Uncontrolled Substances Used to
Commit Date Rape: Hearing Before the Subcomm. on Crime of the Comm. on the Judiciary on H.R. 1530, 105th Cong. 42
(1998) (testimony of Det. Michael Stevens, Orlando Police Dept.).
7where Rohypnol is legal, doctors prescribe it and patients ingest it for legitimate medical purposes.25 In those
countries as well as the United States (U.S.), adolescents and young adults ingest the drug as an intoxicant.
This group reports that the desirable eects of Rohypnol include a \slowed-down, relaxed feeling similar to
being drunk on alcohol,"26 the enhancement of the eects of marijuana and alcohol,27 the ability to be more
talkative and comfortable in social situations,28 and an increased feeling of power and self-esteem.29 Heroin,
cocaine, and ecstasy users also take Rohypnol, reportedly to relieve withdrawal symptoms30 and as \landing
gear" to make the transition from intoxication to sobriety less dicult.31 Finally, rapists use Rohypnol to
incapacitate their victims, as discussed below.32
Rohypnol rst appeared in the U.S. in the early 1990s, and emerged as a drug of abuse in 1993.33 By 1995,
the National Institute on Drug Abuse's (NIDA) Community Epidemiology Work Group (CEWG) reported
that Rohypnol was one of the fastest growing drug problems in Texas and South Florida, and that Rohypnol
misuse was quickly spreading to other parts of the country.34 Several factors may explain the drug's rise
25APRI, supra note 12.
26Calhoun, supra note 18, at 187.
27Id.
28Id.; Anna Maria Daderman and Lars Lidberg, Flunitrazepam (Rohypnol) Abuse in Combination with Alcohol Causes
Premeditated, Grievous Violence in Male Juvenile Oenders, 27 J. Am. Acad. Psychiatry L. 83, 90 (1999).
29Daderman and Lidberg, supra note 28, at 90.
30Saum and Inciardi, supra note 16, at 727; see also James H. Woods and Gail Winger, Abuse Liability of Flunitrazepam, 17
J. Clinical Psychopharmacology 1S, 48S { 49S (Supp. 2 1997).
31Controlled and Uncontrolled Substances Used to Commit Date Rape (testimony of Det. Michael Stevens), supra note 24,
at 30.
32See infra Section I.B.
33Drug Enforcement Agency, Department of Justice, Flunitrazepam, available in APRI, supra note 12, at Ch. 1. Also
contributing to the drug's popularity may have been its link to Nirvana lead signer Kurt Cobain, who in February 1994,
overdosed on Rohypnol in what is believed to be a suicide attempt. Senate Comm. on the Judiciary (Sen. Joseph R.
Biden, Jr.), 103rd Cong., Facing the Future - The Rise of Teen Drug Abuse And Teen Violence 59 (Comm. Print
1995).
34Community Epidemiology Work Group, National Institute on Drug Abuse, Epidemiological Trends in Drug Abuse: Advance
Report (1995). In Florida, between 1992 and 1995, the number of law enforcement cases involving Rohypnol increased by 3,000
percent. See New International Threat of \Date-Rape Drug" Tracking: Hearing Before the Senate Subcomm. on Western
Hemisphere and Peace Corps Aairs of the Comm. on Foreign Relations, 104th Cong. 16 (1996) (testimony of Terrance W.
Woodworth, Drug Enforcement Agency).
8in popularity among younger people: (1) they believed it was safe because it was sold in presealed bubble
packs;35 (2) they thought it could not be detected by urinalysis;36 and (3) they were attracted by its low
price { averaging about three dollars per tablet in the mid-1990s.37
Rohypnol was widely available in the mid-1990s. Before March 1996, individuals with a valid prescription
could bring a ninety-day supply of Rohypnol across U.S. borders.38 A study revealed that in the one-year
period from June 1994 to June 1995, Rohypnol was the second most commonly declared prescription drug
at one Mexican border checkpoint, appearing on approximately forty-three percent of the declarations.39 By
July 1995, almost 1,300 cases of Rohypnol possession were under investigation,40 and in 1995 the federal
government (mostly Customs ocials) seized approximately 225,000 tablets.41 A survey of Dade County,
Florida high school students revealed that 11% reported ever using Rohypnol, while a survey of one hun-
dred one Texas school districts found Rohypnol use in eighty-eight of the districts, with an average of 3.4%
of students in each district having ever used the drug.42 Fourteen percent of students in a district on the
Texas-Mexico border reported ever using Rohypnol.43 NIDA's Monitoring the Future (MTF) national survey
revealed that in 1998,.5% of eighth graders and 1% of tenth and twelfth graders reported using Rohypnol.44
35Drug Enforcement Administration, Flunitrazepam, supra note 14.
36Id.
37See Saum and Inciardi, supra note 16, at 724; Douglas Herring, Getting High from South of the Border: Illicit Smuggling
of Rohypnol as an Example of the Need to Modify U.S. Response to International Drug Smuggling After NAFTA, 18 Loy.
L.A. Int'l & Comp. L.J. 841, 842 { 43 (1996) (quoting a drug treatment expert as stating Rohypnol \will be as popular as
crack because it is so cheap").
38Saum and Inciardi, supra note 16, at 724.
39Trade & Government Memos, F-D-C Rep. (\The Pink Sheet"), Apr. 11, 1996, at 16. The study also found that during
a three-week period in 1995, travelers declared over 100,000 tablets of Rohypnol at one border checkpoint. E. Floyd Phelps,
Ravages of Rohypnol, Security Management, Nov. 1996, at 14.
40Facing the Future , supra note 33, at app. B.
41NIJ, A Report to the Attorney General, supra note 15, at 25.
42Id. at 27 - 28.
43Id. at 28.
44Nora Fitzgerald and K. Jack Riley, Drug-Facilitated Rape: Looking for the Missing Pieces, Nat'l. Inst. Just. J. , Apr.
2000, at 10.
92.
GHB
GHB is a drug that appears naturally in minute amounts in the human body, and was rst synthesized in
the 1920s.45 It is a white powder that is easily formed by adding sodium hydroxide solution to gamma-
butyrolactone (GBL), and is usually available as a odorless, colorless liquid.46 Eects of ingesting GHB,
which substantially increase when combined with the consumption of alcohol, include drowsiness, disorien-
tation, dizziness, slurred speech, nausea, diculty moving, and reduced heart rate and blood pressure.47
At higher doses, coma and death may occur.48 While Rohypnol produces anterograde amnesia and muscle
relaxation, GHB induces disinhibition, and increases sensuality, euphoria, and relaxation.49 Symptoms nor-
mally appear within fteen to thirty minutes of ingesting the drug.50
Like Rohypnol, GHB is known on the street by many dierent names, including Liquid Ecstasy or Liquid
X, Grievous Bodily Harm, Easy Lay, Georgia Home Boy, and Goop.51 And like Rohypnol, GHB has been
and is currently used for several dierent purposes. In the late 1950s and early 1960s, a U.S. pharmaceutical
company worked on developing GHB as an anesthetic agent, but later stopped development.52 Beginning in
the 1970s and continuing today, researchers have studied GHB as a possible treatment for sleep disorders.53
In Europe, GHB is used as an anesthetic, but with decreasing frequency as seizure-like activity became as-
45NIJ, A Report to the Attorney General, supra note 15, at 14.
46Kelly M. Smith, Drugs Used in Acquaintance Rape, 39 J. Am. Pharmaceutical Ass'n. 519, 520 (1999).
47See Smith, supra note 46, at 521; APRI, supra note 12, at 8; Drug Enforcement Administration, An Overview of Club
Drugs, supra note 23, at 3.
48APRI, supra note 12, at 8; Drug Enforcement Administration, An Overview of Club Drugs, supra note 24, at 3.
49Michael Welner and Elizabeth Delfs, Rapist in a Glass? The Big Picture of The Rohypnol Wars, 1 The Forensic Echo 4,
9 (1997). Describing the eects of GHB in less medical terms, one prosecutor notes, \This drug is the closest thing to authentic
Spanish y that I can think of. GHB can remove the impulse control that stops a woman from having sex with a stranger."
Mary K. Moore and Leah Ginsberg, The Date Rapist's Scary New Weapon, Cosmopolitan, Feb. 1, 1999, at 202, quoting Bob
Nichols, Broward County Assistant State Attorney.
50Smith, supra note 46, at 521.
51Drug Enforcement Administration, An Overview of Club Drugs, supra note 24, at 3.
52Id.
53Smith, supra note 46, at 520. This use of GHB will be discussed in more detail infra.
10sociated with it.54 It has also been used with mixed results in Europe to treat alcohol and heroin addiction
and withdrawal.55 In 1977, one study hypothesized that GHB stimulated the eects of growth hormones;
this link, however, has never been proven. Nonetheless, bodybuilders used GHB in the 1980s for its assumed
steroid-enhancing eects, and they could purchase the drug over-the-counter at health food stores.56 Be-
tween June 4 and November 28, 1990, the Food and Drug Administration (FDA) received reports of at least
fty-seven cases of illness due to GHB ingestion, with most patients requiring emergency room care.57 After
receiving these reports, in November 1990, the FDA banned the drug from being sold in the U.S. and warned
consumers that GHB use was unsafe and must stop unless used within an FDA-approved clinical trial.58
Despite this ban, in the 1990s GHB became popular among adolescents and young adults as an illicit
recreational drug used for the euphoria and intoxication it produces, and as a drug to facilitate rape.59
Unsubstantiated rumors linking actor River Phoenix's death in 1993 to GHB are believed to have generated
interest in the drug by recreational users.60 It is an easy drug to manufacture, composed of inexpensive and
readily available ingredients, and in the 1990s many recipes for making GHB on a kitchen stove could be
found on the Internet.61 Those who manufacture GHB can make substantial prots, as an initial investment
54Id.
55NIJ, A Report to the Attorney General, supra note 15, at 14.
56Id.
57Epidemiologic Notes and Reports Multistate Outbreak of Poisonings Associated with Illicit Use of Gamma Hydroxy Bu-
tyrate, 39 MMWR Weekly 861 (1990).
58Food and Drug Administration, GHB Warning (Press Release), Nov. 8, 1990, available at
<http://www.fda.gov/bbs/topics/news/new00032.html> (visited Mar. 27, 2001); see also NIJ, A Report to the Attor-
ney General, supra note 15, at 14.
59See Controlled and Uncontrolled Substances Used to Commit Date Rape (prepared statement of John J. King, Drug
Enforcement Agency), supra note 24, at 53 (stating that three major groups abuse GHB: teenagers and young adults who
take it as an intoxicant or hallucinogenic; bodybuilders who take is as a anabolic agent or sleep aid; and people who use
it to commit sexual assault); NIJ, A Report to the Attorney General, supra note 15, at 14; Drug Enforcement Adminis-
tration, Department of Justice, DEA Press Release Fact Sheet: Gamma Hydroxybutyric Acid, Mar. 13, 2000, available at
<http://www.usdoj.gov/dea/pubs/pressrel/pr031300 01.htm> (visited Mar. 27, 2001).
60Smith, supra note 46, at 520.
61See NIJ, A Report to the Attorney General, supra note 15, at 15; Drug Enforcement Administration, DEA Press Release
Fact Sheet, supra note 59. I conducted my own search on the Internet for recipes for GHB, and easily found some. See, e.g.,
Synthesis for Liquid GHB (visited Jan. 15, 2001) <http://shovelcat.com/ghb info/recipe.html>. GHB diers from Rohypnol
in that it is primarily manufactured in illegal laboratories with little concern for proportions or cleanliness, while Rohypnol is
almost exclusively manufactured in quality controlled, legitimate laboratories. See Trinka Porrata, Gamma Hydroxy Butyrate:
Old Drug -New Tricks, reprinted in Controlled and Uncontrolled Substances Used to Commit Date Rape, supra note 24, at 36.
11of $800 has an approximate street value of $92,000.62 The drug is often sold for approximately $10 at raves
by the drop, capful, or \swig," and mixed into spring water bottles or disguised as mouthwash.63
Between 1990 and March 2000, the Drug Enforcement Administration (DEA) documented over 7,100 over-
doses and law enforcement encounters involving GHB in forty-ve states.64 Between 1995 and March 2000,
DEA documented sixty-three deaths related to GHB.65 A study by the Drug Abuse Warning Network
(DAWN) of selected emergency departments found that GHB mentions had risen from 55 in 1994, to 1,282
in 1998, to 2,973 in 1999.66
Closely related to GHB are GBL and 1,4-butanediol (BD). GBL and BD are industrial solvents, often used in
oor stripper and paint thinner, that are converted into GHB after human consumption.67 Both have been
marketed as dietary supplements under the names Revivarant, RenewTrient, and Blue Nitro Vitality, which
claimed to promote sleep, release growth hormones, enhance sexual and athletic performance, and relieve
depression.68 When the FDA banned the sale and use of GHB, many manufacturers and users switched to
62Ted O'Connell et al., Gamma-Hydroxybutyrate GHB: A Newer Drug of Abuse, 62 American Family Physician 2478 (Dec.
1, 2000).
63Drug Enforcement Administration, DEA Press Release Fact Sheet, supra note 59. See also Community Epidemiology
Work Group, National Institute on Drug Abuse, Epidemiological Trends in Drug Abuse: Advance Report (2000), available at
<http://www.nida.nih.gov/CEWG/AdvancedRep/6 20ADV/0600adv.html> (visited Mar. 27, 2001).
64Drug Enforcement Administration, DEA Press Release Fact Sheet, supra note 59. This gure includes federal, state, and
local cases of possession, tracking, clandestine manufacturing, and forensic analyses. Id. One study found sixty-nine cases of
acute poisoning and one death attributed to GHB during a one-year time period in New York and Texas. Gamma Hydroxy
Butyrate Use: New York and Texas, 1995-1996, 46 MMWR Weekly 281 (1997).
65Id.
66Oce of Applied Studies, Substance Abuse and Mental Health Services Administration, Club Drugs, The D.A.W.N.
Report, Dec. 2000, at 3, available at <http://www.samhsa.gov/oas/clubdrug.pdf> (visited Mar. 27, 2001). It is important to
note that DAWN's gures do not include any cases in which drugs are given to others without their knowledge. See id. at 10.
Despite these statistics, a few commentators and doctors continue to claim that GHB is a perfectly safe dietary supplement.
See, e.g., Ward Dean et al., GHB: The Natural Mood Enhancer (1997); Joshua H. Beisler, Dietary Supplements and
Their Discontents: FDA Regulation and the Dietary Supplement Health and Education Act of 1994, 31 Rutgers L. J. 511
(2000). These commentators contend that \GHB may be the safest, most eective substance ever developed" for a variety
of purposes, and that the FDA and DEA have manufactured a \GHB-poisoning/date-rape crisis. Dean, at back cover. One
argues that \[t]he scientic evidence not only fails to substantiate [allegations that GHB causes comas and seizures], but bluntly
contradicts them as well." Beisler, at 541. These statements about GHB's safety are simply untrue, as articles in such highly
respected medical journals as the New England Journal of Medicine demonstrate. See, e.g., Deborah L. Zvosec et al., Adverse
Events, Including Death, Associated with the Use of 1,4-Butanediol, 344 New Eng. J. Med. 87 (2001).
67Zvosec, supra note 66.
68See Adverse Events Associated with Ingestion of Gamma-Butyrolactone Minnesota, New Mexico, and Texas, 1998-1999,
48 MMWR Weekly 137 (1999); Zvosec, supra note 66.
12GBL and BD.69 These chemicals, once converted to GHB, have similar adverse eects, and researchers have
documented poisonings and deaths after consumption of these chemicals as well.70
The above information on GHB does not paint a pretty picture, yet some people regard GHB as their sav-
ior.71 As mentioned above, beginning in the 1970s, researchers have studied GHB as a potential treatment
for the disease of narcolepsy.72 In 1994, at the urging of the FDA's Oce of Orphan Products, Orphan
Medical began developing GHB as a narcolepsy treatment, under the name Xyrem.73 In March 1998, it
received the results of a two-year clinical study, which showed that Xyrem reduced sudden sleep attacks and
left many patients feeling less sleepy during the day.74 Sharon Fitzgerald, a fty-six year old judge who
participated in the Xyrem clinicals, described the eects of Xyrem: \My sleep was better. There were no
more horrible dreams. I could practice law, and play with my grandkids. It is a miracle drug."75 GHB thus
poses both great benets and harms to dierent groups of people.
3.
Ketamine
69Zvosec, supra note 66.
70See Adverse Events, supra note 68 (describing seven cases of GBL toxicity and summarizing an additional thirty-four cases
of GBL toxicity); Zvosec, supra note 66 (describing eight patients who had ingested BD and concluding that the health risks
of BD are similar to those of GHB and GBL, including acute toxic eects, death, addiction, and withdrawal).
71Mitchell Zucko, Its Use as Narcolepsy Treatment Splits Agencies on `Date-Rape' Drug, Boston Globe, Apr. 20, 1999,
at A1.
72The pharmaceutical company currently developing GHB describes narcolepsy as follows:
Narcolepsy patients experience profound sleepiness in the daytime { so severe that they often nd it dicult to drive, hold
a job or perform other seemingly `normal' tasks. In addition to excessive daytime sleepiness, some narcoleptic patients also
experience cataplexy, which is a sudden loss of muscle control which may cause the patient to collapse. Some patients nd
themselves virtually unable to function as they may collapse from 25-50 times in one day.
Controlled and Uncontrolled Substances Used to Commit Date Rape (letter from Orphan Medical, Inc.), supra note 24, at
63. Orphan Medical, Inc., was formed in 1994 solely to develop and commercialize treatments for rare diseases. Id. at 64.
Narcolepsy aects approximately 180,000 Americans, making the market too small for most pharmaceutical rms to nd it
worthwhile to develop a treatment. Jill P. Barshay, One Drug Two Faces, Star Tribune (Minneapolis), Aug. 6, 2000, at 1D.
73See Controlled and Uncontrolled Substances (letter from Orphan Medical, Inc.), supra note 24, at 64; Barshay, supra note
72.
74Barshay, supra note 72.
75Ellen Licking, Jekyll and Hyde Drug, Business Week, Oct. 23, 2000, at 96.
13Ketamine hydrochloride (ketamine), a chemical cousin of phencyclidine (PCP), is a dissociative anesthetic.76
It was developed in the 1960s and is used in the U.S. as a general anesthetic in emergency and veterinary
medicine.77 It is marketed for human use under the trade name Ketalar, and for veterinary use under names
including Ketaset, Ketaget, and Vetalar.78 Side eects produced by the drug include a feeling described
as oating above one's own body, hypertension, vomiting, dizziness, disorientation, vivid dreams, halluci-
nations, delirium, anxiety, insomnia and amnesia.79 Symptoms begin within fteen to twenty minutes of
taking the drug.80
Ketamine is known on the street as K, Special K, Vitamin K and Cat Valium.81 Ketamine rst became
popular on the streets in the early 1970s, in part due to John Lilly's enthusiastic description of his exper-
imentation with what he called Vitamin K.82 Recreational drug users enjoyed ketamine's PCP-like eects,
with the addition of the visual eects of lysergic acid diethylamide (LSD), and the fact that the experience
lasts an hour or less as compared to PCP's several hours.83 Ketamine use experienced a resurgence in the
1990s as the rave scene developed.84 The DEA describes two ketamine experiences: \Low doses of the drug
produce an experience referred to as `K-Land,' a mellow, colorful `wonder world.' Higher doses produce an
76James W. Dotson et al., Ketamine Abuse, 25 J. Drug Issues 751 (1995). Dissociative drugs are those that dis-
tort perceptions of sight and sound and produce feelings of detachment from one's environment and self. National
Institute on Drug Abuse, Hallucinogens and Dissociative Drugs, Research Report Series, March 2001, available at
<http://www.nida.nih.gov/ResearchReports/hallucinogens/hallucinogens.html> (visited Apr. 15, 2001).
77Dotson, supra note 76, at 752; Smith, supra note 46, at 523.
78Scheduled of Controlled Substances: Placement of Ketamine into Schedule III, 64 Fed. Reg. 37,673 (1999) (to be codied
at 21 C.F.R. pt. 1308).
79Dotson, supra note 76, at 753; Smith, supra note 46, at 523 { 24.
80Smith, supra note 46, at 521.
81Drug Enforcement Agency, An Overview of Club Drugs, supra note 24, at 3.
82Dotson, supra note 76, at 753. Lilly, the rst neuroscientist to communicate with dolphins, wrote the book \The Scientist:
A novel autobiography" in 1978, and was a character in the 1980 movie \Altered States." Id. at 756; John Cloud, Is Your Kid
on K? A Hot New High Hits Main Street, and, Nope, It Isn't a Breakfast Cereal, Time, Oct. 20, 1997, at 90. Timothy Leary,
a friend of Lilly's deemed the \acid guru," also promoted the use of ketamine in the 1970s. Id. at 754.
83See Drug Enforcement Agency, An Overview of Club Drugs, supra note 24, at 3; Drug Enforcement Agency, De-
partment of Justice, DEA Press Release: DEA to Control `Special K' for the First Time, July 13, 1999, available at
<http://www.dea.gov/pubs/pressrel/pr071399.htm> (visited Mar. 27, 2001). Although the \trip" lasts only up to an hour,
the user's senses, judgment and coordination can be aected for eighteen to twenty-four hours. Oce of National Drug Control
Policy, Facts & Figures: Club Drugs, supra note 22. One author describes ketamine as prompting existential thoughts, giving
it a spiritual dimension. Alex Bellos, The Animal Magic Trap, Guardian (London), Apr. 1, 1997, at T8.
84Dotson, supra note 76, at 754. Its growing popularity was perhaps partially sparked by, and reected in, an \X-Files"
episode in which agent Fox Mulder took ketamine to recover lost memories and a song by the Chemical Brothers titled \Lost
in the K-Hole." See Cloud, supra note 82.
14eect referred to as `K-Hole,' an `out of body,' or `near-death' experience."85 Ketamine has also been linked
to drug-facilitated rape.86 The drug is available legally only in liquid form by prescription, but can easily
be converted to powdered form. When used illicitly, ketamine is injected, smoked, snorted, swallowed, or
placed in drinks.87 Each dose costs on average $20.00.88 Robberies of veterinary clinics are the primary
source of illicit ketamine.89
Between 1992 and July 1999, the DEA learned of over 500 reports of the sale and/or use of ketamine in
schools, college campuses, night clubs and raves.90 DAWN's study of selected emergency departments found
1,173 mentions of ketamine use, with an increase from 19 mentions in 1994 to 396 in 1999. 91 DAWN's
study of selected medical examiners found 46 deaths associated with the drug.92
B.
Drug-Facilitated Sexual Assault
1. The Problem
Each of the drugs described above has been used to facilitate rape.93 In the typical case, a woman is
at a restaurant, rave, party, or club, when a man secretly slips a drug into her drink. As she drinks it, she
begins to feel disoriented and sick. The next thing she remembers is waking up, with unexplained gaps in her
85Drug Enforcement Agency, An Overview of Club Drugs, supra note 24, at 3.
86Smith, supra note 46, at 523.
87Drug Enforcement Agency, An Overview of Club Drugs, supra note 24, at 3; Smith, supra note 46, at 523.
88Drug Enforcement Agency, An Overview of Club Drugs, supra note 24, at 3.
89Drug Enforcement Agency, DEA Press Release: DEA to Control \Special K" for the First Time, supra note 83. See also
Lois R. Shea, Drug Thieves Hit Veterinarians: Anesthetic's Popularity Makes Clinics Targets, Boston Globe, Dec. 19, 1999,
at B16; Katie Merx, Thieves Steal Date-Rape Drug: Special K, an Animal Anesthetic, is Latest Used in Sex Assaults, Detroit
News, Apr. 26, 1999, at C5.
90Drug Enforcement Agency, DEA Press Release: DEA to Control \Special K" for the First Time, supra note 83.
91See Oce of Applied Studies, Substance Abuse and Mental Health Services Administration, Club Drugs, supra note 66, at
3.
92Id. at 1.
93See Smith, supra note 46.
15memory, often with signs of physical trauma or sexual activity.94 Drugs facilitate sexual assault by making
it easy for perpetrators to gain control of their incapacitated victims, because they do not have to overcome
any form of resistance or worry about their victims calling out for help. Rapists prevent their victims from
detecting threats to their safety by using an invisible weapon that is hidden in a drink, a weapon that
prevents women from exercising any form of self-defense. Furthermore, rapists may appear to be rescuing
their victims, who seem drunk to observers who watch the rapists carry or lead their victims out of the party
or bar.
Drug-facilitated rapes dier from other forms of rape in several ways. They are most likely reported less
often than other types of rape because the eects of the drugs may prevent victims from going to a hospital
or police station until several hours or days have passed, the victims may be confused or uncertain about
what happened, and may be reluctant to accuse someone without memory of the rape. When victims do
report drug-facilitated rapes, they often encounter police and prosecutor suspicion, disbelief, or frustration,
as they are unable to give a clear description of the rape. This inability to recall information that could help
the investigation may add to the victims' sense of helplessness. Some people minimize drug-facilitated rape
victims' trauma, mistakenly believing that a victim is better o not remembering the rape. While rape is
deeply traumatic for all victims, drug-facilitated rape victims' must deal with an additional extreme form of
powerlessness that stems from their inability to remember the assault; they must experience the horror and
humiliation of not knowing what happened to them.95 Finally, drugging is a unique form of trauma, one
94See Fitzgerald and Riley, supra note 44, at 9; Deirdre Anglin et al., Flunitrazepam and Its Involvement in Date or
Acquaintance Rape, 4 Acad. Emergency Med. 323, 324 (1996); Gail Abarbanel, Learning From Victims, Nat'l. Inst. Just.
J. , Apr. 2000, at 11. Gail Abarbanel is the director of the Rape Treatment Center at Santa Monica { UCLA Medical Center.
The remainder of this paragraph and the next summarize Ms. Abarbanel's insights on what has been learned from victims of
drug-facilitated rape. See Abarbanel, at 11 { 12.
95Bonnie Campbell, Director of Department of Justice's Violence Against Women Oce, explains: \Sexual assaults involving
rape drugs can be doubly devastating to victims. Not only do these women live with the physical eects of these drugs, they
must also face the daily mental torment of not knowing what happened to them while they were drugged." Justice Department
Develops New Tools to Fight Drug-Facilitated Sexual Assault, PR Newswire, May 18, 1999. Senator Joseph Biden has
hypothesized: \It must be the most intolerable circumstance a person could be in { to be abused like that, know who abused
16that some victims describe as \mind rape," and should be recognized as a distinct act of victimization.
The above description of drug-facilitated rape cannot fully convey the true horror of the crime. Testimony
to a Congressional subcommittee by victims of Rohypnol-related rapes paints a more detailed picture:
Real briey, I was out at a local nightclub. I was newly separated from my husband.
A girl introduced me to the rapist and he slipped [Rohypnol] in my drink. Within a matter
of minutes { I was still sitting on the stool { I was completely out.
I don't know how we got back to my house or how any of the events unfolded except that I
did come to for a good 45 seconds to a minute while he was raping me.
When I came to the next morning, I still was totally disoriented. All I knew was I had to
get to my job. I didn't know what happened. It took a good 2 days for me to come out of
it....
The way it ruined my life, I was living in a mobile home that I had bought for me and my
three children. After the rape had occurred and I nally had put two and two together and,
you know, made my police report, and things started to come together, I could not stand
being in the home. I ended up selling it 3 months ago for a mere $1,000 to get out, just to
get out.
I would have night terrors of him burning my home down at night with me and my three
children in it. I had horrible nightmares. I've been in therapy now since it happened. I
spend $100 a week just on therapy, not to mention what I spend on the medication for
depression. I have not been able to keep a job. I get a job and I just can't really function.
And I have a 17 year background in retail management.
It has just completely destroyed my life, the way people have acted { like, did you do
something wrong, you know, or what were you doing?
This guy knew he was going to drug and rape a woman ahead of time.... I have no way of
knowing how much he gave me. I have no way of knowing if he acted alone or if there were
other people in my home. I have no way of knowing if he took movies or pictures. Thank
god my children were not at home.
I've been through feeling shame, through being scared, through being angry. I've worked
very hard this past year on speaking out against it. At rst, I was in the shadow. Then I
realized that I cannot make a statement to other women to not be a victim if I'm hiding
behind a curtain. OK, that makes me look like I've done something wrong, and I haven't.
I have not done anything wrong. I just went out to get a bite to eat and have a nightcap
with my girlfriend.
At that time, I was on medication. Now this guy didn't know this. I could have ended up
in a coma. I have three small children to take care of. Then they had to deal with the
depression that I went through afterward....
One big question I want to raise is if this man had AIDS, I'd probably be sitting here with
4 years left to my life right now when I've got babies at home.96
you, but you cannot recall enough specics to be able to make that person pay." See New International Threat of \Date-Rape
Drug" Tracking (statement of Senator Joseph R. Biden, Jr.), supra note 34, at 8. This horror of not remembering stands
in sharp contrast to the feeling experienced by other rape victims of being unable to forget the rape. For these victims, the
trauma is reexperienced repeatedly through thoughts, ashbacks, and nightmares. Abarbanel, supra note 94, at 12.
17Another victim of the same rapist testied:
For me it was a little bit dierent. I was in a friend's home and this was someone
that I trusted. He oered me a coke and I drank it. Fifteen minutes after I drank the coke
I started to feel dizzy. So I asked if I could lie down on the couch. I did. And that's all I
remember.
I woke up the next morning in his bed without my clothes and he made the comment to me
that he had waited 5 years for this. So this was not something that just happened. This
was planned.
I feel that Rohypnol is a weapon. I don't see it as having any use at all, any use at all,
whatsoever. It's a weapon and anybody can get hold of it. You can't go back and replace
the time that I've lost, the a pain that I've been through.
Lisa brought up the point about diseases. There's also pregnancy. I became pregnant as a
result of this. I had to go through that also.97
2. Its Prevalence
Estimates of the prevalence of all types of sexual assault vary. One longitudinal survey found that 13% of
the adult women surveyed reported having been raped once, which leads to an estimate of approximately
693,000 adult women being forcibly raped each year.98 Another study, the National Crime Victimization
Study, found that a nationally representative sample of households disclosed 430,000 sexual assaults in 1994.99
Yet another researcher estimated that 25% of American women will be raped during their lifetimes.100 A
great majority of rapes, perhaps as many as 90%, will not be reported.101 Women often do not report rapes
because they are scared of retaliation by their rapists, embarrassed, blaming themselves, in fear of the way
the medical and legal system will treat them, or hopeless about a just outcome.102 An estimated 80% of all
rapes are \date" or acquaintance rapes.103
Not surprisingly, a report by the Department of Justice Drug-Facilitated Rape Working Group found that
98NIJ, A Report to the Attorney General, supra note 15, at 9. The National Victim Center and the National Crime Victims'
Research and Treatment Center conducted this study. Id.
99Id. at 10.
100Smith, supra note 46, citing I.L. Schwartz, Sexual Violence Against Women: Prevalence, Consequences, Societal Factors,
and Prevention, 7 Am. J. Preventative Med. 363 (1991).
101NIJ, A Report to the Attorney General, supra note 15, at 10.
102See id. The choice not to report due to fears of medical treatment appear to be well-founded. In 1997, the American Medical
Association gave the United States a D- for its evaluation and treatment of rape victims. See Laura Slaughter, Involvement of
Drugs in Sexual Assault, 45 J. Reprod. med. 425 (2000).
103NIJ, A Report to the Attorney General, supra note 15, at 10.
18it is impossible to know how many drug-facilitated rapes have occurred in the U.S.104 Statistics do not exist
for this crime. The report concluded:
Despite the relatively small number of cases where forensic evidence has been found to link a
rape with one of these drugs, rape crisis centers and law enforcement agency personnel tell of
growing numbers of cases where women believe that they have been drugged and raped. It is
not possible to estimate the number of incidents that have occurred. Information gathered
for this report suggests that its magnitude is small. This issue, however, is very serious and
warrants attention.105
Despite the lack of statistical data, some unscientic pieces of information do indicate that drug-facilitated
rape is occurring. A FDA magazine reported that in response to a Glamour magazine survey, nineteen
percent of female college students said they knew someone who had been raped after ingesting GHB.106
NIDA's CEWG reported that in 1998, GHB was used in an increasing amount of rape cases in Los Angeles
and Seattle.107 The Director of the Florida Poison Control Center testied in front of Florida's legislature
that during the rst six months of 1996, the Center was consulted in over one hundred cases involving con-
rmed Rohypnol rapes, and an additional two hundred cases where Rohypnol was suspected.108 Based on
a case where the arrest of three teenagers for using Rohypnol to rape a girl led to additional complaints of
sexual assault from four other girls, a Florida detective stated, \The natural extrapolation here is that there
are probably many { perhaps hundreds or thousands of women { who will never report being victimized
in Rohypnol-enhanced sexual assaults."109 In March 1999, DEA reported to Congress that it knew of nine
individuals convicted of sexual assault cases involving Rohypnol, and was aware of seventeen other cases
104NIJ, A Report to the Attorney General, supra note 15, at 7; see also Controlled and Uncontrolled Substances Used to
Commit Date Rape (prepared statement of John J. King), supra note 24, at 54, which explains that measuring the prevalence
of drug-facilitated sexual assault is \almost impossible" because the normal problem of underreporting of sexual assault cases
is exacerbated in drug cases due to \amnesia, loss of inhibitions, inability to control what is happening... [,] the lack of data
base information of drug-induced sexual assaults and the need to protect the privacy of victims."
106Tamar Nordenberg, Raising Consciousness About Drugs and Rape, FDA Consumer, Mar. 1, 2000, at 14.
107See Community Epidemiology Work Group, National Institute on Drug Abuse, Epidemiological Trends in Drug Abuse:
Advance Report (1999), available at <http://165.112.78.61/CEWG/AdvancedRep/699ADV/699adv.html> (visited Mar. 27,
2001).
108New International Threat of \Date-Rape Drug" Tracking (prepared statement of Robert Nichols), supra note 34, at 87.
109Michael F. Conlan, Congress Also Cracking Down on Drugs Used Illegally, Drug Topics, Aug. 19, 1996, at 98, quoting
Det. Sgt. David Robshaw of the Broward County Sheri's Oce.
19from 1994 to 1998 in which the evidence suggested Rohypnol was involved.110
The Violence Against Women Program of the American Prosecutors Research Institute (APRI) is currently
collecting data on all drug-facilitated rape cases. As of 1999, it had counted eight cases of rape involving
Rohypnol, ve cases of rape involving GHB, and three cases involving other drugs.111 Many of the cases
reported by the APRI and by newspapers involve one or two men drugging and then raping a number of
women over a period of time,112 and the DEA has reported that Rohypnol has been used by street gangs to
\gang rape" girls as an initiation ritual.113 Although the APRI does not list any, newspaper articles show
that drug-facilitated sexual assault cases involving ketamine, although less frequent than those involving
GHB and Rohypnol, do exist.114
Some studies have attempted to determine which drugs are used most frequently in drug-facilitated rape
cases. Homann-La Roche, the manufacturer of Rohypnol, funded one of these studies.115 Since 1996, the
company has maintained a system for analyzing urine samples from victims suspected of being drugged with
unitrazepam.116 Any emergency department, law enforcement agency, or rape crisis center may submit
110Date Rape Drugs: Hearing Before the House Subcomm. on Oversight and Investigations of the Comm. on Commerce,
106th Cong. 63 (1999) (prepared statement of Terrance W. Woodworth, Drug Enforcement Agency).
111APRI, supra note 12, at Ch. 4.
112See, e.g., Introduction supra; Rohypnol Case Study: \Serial Rapist," in APRI, supra note 12, at Ch. 4 (summarizing
the case against Steven Sera for raping and videotaping four women in Arkansas, Missouri, and Texas after drugging them
with Rohypnol); Alex Tesniowski, Taped in the Act; Accused of Rape, A Cosmetics Heir Insists that the Sex was Consensual,
People, Oct. 20, 2000, at 151 (describing the charges against Andrew Luster for allegedly drugging as many as fteen women
with GHB and then raping and videotaping them); Jay Croft, Brothers Are Convicted in `Date Rape' Drug Case, Atlanta J.
& Const., Feb, 17, 1999, at 3C (describing two brothers as giving two Georgia State University students GHB, and then raping
one as the other lay unconscious on the bathroom oor); Michele Munz, Man Accused of Using Date-Rape Drug is Held on
New Charges, St. Louis Post-Dispatch, Dec. 2, 2000, at 13 (stating that a man accused of raping one woman and drugging
three others with GHB was arrested for possessing ketamine); Jean Seligmann and Patricia King, `Rooes': The Date-Rape
Drug, Newsweek, Feb. 26, 1996, at 54 (describing how Mark Perez, the rapist of the two women whose testimony is printed
above, bragged to his friends that he had used Rohypnol to drug and rape a dozen women).
113See New International Threat of \Date-Rape Drug" Tracking (prepared statement of Terrance W. Woodworth,) supra
note 34, at 17.
114See, e.g., Introduction supra; Man Pleads Guilty to Attempted Sexual Assault, Ariz. Republic, Nov. 18, 1999, at B5
(stating that a former animal control ocer who bragged about using ketamine to rape women pled guilty to attempted
sexual assault); Alison Bass, 2d Ex-Patient of Doctor Charges Sexual Abuse, Boston Globe, Apr. 13, 1989, at 46 (describing
allegations that a doctor administered ketamine to a patient and then had sex with her). In July 1999, the DEA Acting
Administrator stated that \although to date there has been only one documented case nationwide in which ketamine was used
to facilitate rape, it has the same potential as [Rohypnol] and [GHB]." Drug Enforcement Agency, DEA Press Release: DEA
to Control \Special K" for the First Time, supra note 83.
115NIJ, A Report to the Attorney General, supra note 15, at 30.
116Michael E. Mullins, Laboratory Conrmation of Flunitrazepam in Alleged Cases of Date Rape, 6 Acad. Emergency Med.
20such a sample to a laboratory in Mississippi, which analyzes the sample at no charge.117 In order to be
eligible for analysis, the sample must have been collected within seventy-hours of the assault.118 As of May
29, 1998, the laboratory had tested 1,077 urine samples.119 The study found: 59% of the samples contained
one or more detectable drugs or alcohol; 36% contained alcohol; 18% contained marijuana; 12% contained a
BZ other than unitrazepam; 4% contained GHB; and.06% contained unitrazepam.120 The selection biases
and inadequate documentation of this study, however, make it inappropriate to believe these numbers are
representative of the larger population.121
In sum, a clear picture of how many drug-facilitated rapes occur and a breakdown by drug do no exist.
Rape crisis counselors and law enforcement personnel suggest that this crime occurs at signicant levels,
but researchers have not yet developed the tools to measure accurately the problem.122 One fact is certain,
however: during the 1990s, the media and the government believed that a \date-rape drug" crisis was oc-
curring.123 The next section describes the actions taken by the government and other actors in response to
the perceived crisis.
966 (1999).
117Id.
118Id.
119Id. For details on the methods used to test the samples, see id.
120Id.
121Id.; NIJ, A Report to the Attorney General, supra note 15, at 31. Selection biases include the following: each victim had
to report her rape to an emergency department, law enforcement agency, or rape crisis center within seventy-two hours of the
assault; those victims who did report needed to suspect being drugged; testing was voluntary, so a victim who was worried
about revealing her substance abuse might refuse testing; some agencies might not submit the samples due to their perception
that a conict of interest existed because Homann-La Roche manufactures both Rohypnol and the detection system for it;
and some agencies might have had testing performed at local laboratories. See Mullins, supra note 116. The study was not
adequately documented in that there were no monitoring systems or protocol documents to ensure that all eligible cases had a
chance of inclusion in the study. NIJ, A Report to the Attorney General, supra note 15, at 31.
122In its assessment of the few current studies, the Department of Justice's (DOJ) Drug Facilitated Rape Working Group
concluded:
a starting point for any study to document a drug-facilitated rape would be to collect both a urine sample and interview the
study participants. Additionally, the interview instrument should distinguish between recreational (voluntary) use of Rohypnol
and clandestine (involuntary) use of Rohypnol. None of the four review studies used both interviewing and urine testing.
Therefore, we can not be certain that any of these studies have positively identied any cases of drug-facilitated rape, let alone
helped establish the scale of the problem.
NIJ, A Report to the Attorney General, supra note 15, at 34.
123See the DOJ Drug Facilitated Rape Working Group's analysis of the media coverage of drug-facilitated rape, nding 454
articles between 1990 and 1998, and a much greater interest in Rohypnol than GHB, ketamine, or alcohol. Id. at 18 { 23.
21II. The Response to the Problem of Drug-Facilitated Sexual Assault
This section divides those who have responded to the problem of drug-facilitated sexual assault into three cat-
egories { federal government, state government, and non-governmental actors { and describes what measures
these actors have taken.
A.
The Government's Response
The government's responses to Rohypnol, GHB, and ketamine will be analyzed separately, as the response
to each of the drugs has diered. Before the individual drugs are discussed, a brief overview of the scheduling
process used to control drugs is presented as knowledge of this process is essential for understanding the
government's response to drug-facilitated rape.
1.
The Controlled Substances Act
Congress passed the Controlled Substances Act (CSA)124 in 1970 in an attempt to synthesize previous drug
laws and achieve a more coherent framework in this area of the law.125 Briey, the CSA requires:
the registration of every person in the legitimate chain of drug distribution, detailed record
keeping, and production quotas for the manufacture of certain drugs,... strict import and
export limitations, [and] [h]arsh penalties for those engaged in the illicit drug trac.126
124This Act is part of the Comprehensive Drug Abuse Prevention and Control Act of 1970, Pub. L. No. 91-513, 84 Stat. 1236
(1999).
125Control of Amphetamine Prescription and Production: Critical Analysis of Federal, State and Local Eorts to Control
Amphetamine Abuse, 8 Colum. J.L. & Soc. Probs. 401, 410 (1972).
22It establishes ve schedules of controlled substances, placement into which depends on a substance's po-
tential for abuse, actual medical value, and potential for psychological or physical addiction.127 Schedule
I substances have a high potential for abuse, no currently accepted medical use in the U.S., and may lead
to severe physical or psychological dependence. At the opposite end of the spectrum, schedule V drugs
have a low potential for abuse relative to the substances in schedule IV, a currently accepted medical use
in the U.S., and may lead to only limited physical or psychological dependence relative to other substances
in schedule IV.128
The federal government may schedule drugs in ve dierent ways: (1) Congress originally controlled many
substances when it enacted the CSA in 1970;129 (2) Congress may control a drug through legislation;130
(3) the Attorney General may control a drug to fulll treaty obligations;131 (4) DEA can use an emergency
provision to temporarily schedule certain substances not subject to an investigational new drug application
if an imminent hazard to the public health exists;132 and (5) the Attorney General, or by delegation the
DEA, may schedule a drug after a detailed evaluation.133 When making this evaluation, the Attorney
General is required by the CSA to consider eight factors:
(1) [The substance's] actual or relative potential for abuse. (2) Scientic evidence of its
pharmacological eect, if known. (3) The state of current scientic knowledge regarding
the drug or other substance. (4) Its history and current pattern of abuse. (5) The scope,
duration, and signicance of abuse. (6) What, if any, risk there is to the public health. (7)
Its psychic or physiological dependence liability. (8) Whether the substance is an immediate
precursor of a substance already controlled under this title.134
To begin the process of evaluating a substance, the Attorney General must request from the Secretary of the
Department of Health and Human Services (DHHS) a scientic and medical evaluation and recommendation
regarding scheduling.135 When making this recommendation, the Secretary must take into consideration
13521 U.S.C. x 811(b). DHHS, DEA or any interested person by petition may initiate proceedings to add, delete, or change
the schedule of a drug. Date Rape Drugs (prepared statement of Nicholas Reuter), supra note 110, at 70.
23the above factors (2), (3), (6), (7), and (8), and any scientic and medical considerations involved in factors
(1), (4), and (5).136 The Secretary's recommendation is binding on the Attorney General, so that if the
Secretary recommends that a drug not be scheduled, the Attorney General may not schedule it.137 The
Secretary of DHHS relies upon FDA and NIDA to perform the medical and scientic evaluation,138 and the
two agencies cooperate in this endeavor according to a Memorandum of Understanding.139 FDA has stated
that its average response time to a scheduling request is eight to ten months.140
In the past, Congress has bypassed this complicated process and instead legislatively scheduled drugs. In
1984, Congress moved Methaqualone (Quaaludes) from schedule II to schedule I, in response to the drug's
increasing abuse by young adults who would mix it with alcohol and other drugs and often die.141 Congress
made this change despite the fact that Methaqualone had a recognized legitimate use in the U.S. at the
time.142 Similarly, in 1990, with the Anabolic Steroids Control Act of 1990, 143 Congress added anabolic
steroids to schedule III.
State governments also control substances. Most states have adopted the Uniform Controlled Substances
Act (Uniform Act),144 which was drafted during the same year that Congress enacted the federal Controlled
Substances Act. The purpose of the Uniform Act was to provide \an interlocking trellis of Federal and State
law to enable government at all levels to control more eectively the drug abuse problem."145 Mirroring
136Date Rape Drugs (prepared statement of Nicholas Reuter), supra note 110, at 70.
137Id.
138Id.
139Memorandum of Understanding With the National Institute of Drug Abuse, 50 Fed. Reg. 9,518 (1985). Within the FDA,
the Oce of Health Aairs coordinates the evaluation, while the Center for Drug Evaluation and Research with assistance from
others within the agency conducts the actual review. An Advisory Committee of non-FDA employees reviews the data as well.
FDA consults with NIDA while conducting its evaluation. The Interagency Drug Scheduling Working Group, which includes
representatives from FDA, NIDA, and the Substance Abuse and Mental Health Services Administration, meets occasionally
during the review to discuss the evaluation's progress. Once a recommendation is made it is forwarded to the Assistant
Secretary of Health, who makes the nal determination of what recommendation to send to DEA. See Date Rape Drugs
(prepared statement of Nicholas Reuter), supra note 110, at 70 - 71.
140Date Rape Drugs (prepared statement of Nicholas Reuter), supra note 110, at 71.
141Facing the Future , supra note 33, at 71.
142Id.
143Pub. L. No. 101-647, 1901-1907, 104 Stat. 4851 (codied in scattered sections of 21 U.S.C. and 42 U.S.C. (1999).
1449 U.L.A. 187.
145McLaughlin, supra note 126, at 571.
24the federal law, the Uniform Act establishes ve schedules based on a substance's potential for abuse and
medical utility.146 It also contains a provision that makes a federal scheduling decision a \trigger" for the
states to take the same action, so that once the federal government schedules or reschedules a drug, the
states are obliged to do so as well after a thirty-day period unless an objection is made.147 States may
also legislatively or administratively schedule drugs when Congress has not yet done so. Thus at times the
federal and states government place the same drug into a dierent schedule. The following descriptions of
the federal and state scheduling responses will highlight these dierences.
2.
The Federal Response
a.
Rohypnol
The rst ocial response to the increase in Rohypnol abuse and the growing perception of its use as a date-
rape drug occurred on March 4, 1996, when President Clinton ordered the U.S. Customs Service to stop
146Id.
147Telephone Interview with Marcia Lee, Sta Member of Senator Joseph Biden (Apr. 19, 2001). The relevant provision
states:
If a substance is designated, rescheduled, or deleted as a controlled substance under federal law, the [appropriate person or
agency] shall similarly treat the substance under this [Act] after the expiration of 30 days from the date of publication in the
Federal Register of a nal order designating the substance as a controlled substance or rescheduling or deleting the substance
or from the date of issuance of an order of temporary scheduling... unless within the 30-day period, the [appropriate person
or agency] or an interested party objects to the treatment of the substance. If no objection is made, the [appropriate person
or agency] shall adopt and publish, without making the determinations or ndings required by subsections (a) through (d)
or Section 203, 205, 207, 209, or 211, a nal rule treating the substance. If an objection is made, the [appropriate person or
agency] shall make a determination with respect to the treatment of the substance as provided by subsections (a) through (d).
Upon receipt of an objection to the treatment by the [appropriate person or agency], the [appropriate person or agency] shall
publish notice of the receipt of the objection, and action by the [appropriate person or agency] under this [Act] is stayed until
the [appropriate person or agency] adopts a rule as provided by subsection (d).
Unif. Controlled Substances Act, x201, 9 U.L.A. 187.
25allowing the drug to enter the U.S. under travelers' personal use exemptions148 and to seize any Rohypnol
entering the U.S.149 Then on March 25, 1996, DEA sent a letter to DHHS requesting a scientic and medical
evaluation of Rohypnol. In its letter, DEA stated: \The United States (U.S.) is experiencing an epidemic of
abuse of the benzodiazepine, unitrazepam.... Actual abuse data indicate that unitrazepam meets all the
requirements for placement into Schedule I."150 In 1971, the United Nations Commission on Narcotic Drugs
had added unitrazepam, as well as twenty other BZs, to schedule IV of the Convention on Psychotropic
Substances because it had a legitimate medical use in most parts of the world.151 Once the U.S. signed this
Convention, it too was required to temporarily placed Rohypnol in schedule IV, which it did in 1984.152
Rohypnol remained in Schedule IV for the decade that followed, even though it had no legitimate medical
use in the U.S. For \business reasons," Homan-La Roche never sought approval to market the drug in the
U.S.153
148Under DEA regulations, a person may bring into the U.S. a three month supply of a drug for personal medical use if it
has been lawfully obtained in a foreign country, unless the importation is clearly prohibited by other federal laws. See New
International Threat of \Date-Rape Drug" Tracking (prepared statement of Maria Herrera, U.S. Customs Service), supra note
34, at 22. On March 5, 1996, Treasury Secretary Robert Rubin and U.S. Customs Commissioner George Weise announced that
the importation of Rohypnol was banned. They explained that the importation of Rohypnol for personal use was prohibited
by the Federal Food, Drug, and Cosmetic Act because it was an unapproved new drug. Id.
149See President William J. Clinton, Remarks at the Swearing-in Ceremony for the New Director of the Oce of National
Drug Control Policy (Mar. 6, 1996) (transcript available from Federal Document Clearing House Political Transcripts). Seizures
of Rohypnol fell dramatically after this new policy took eect, but began to rise again by 1998. See Date Rape Drugs (prepared
statement of Terrance W. Woodworth), supra note 110, at 60 (34,000 tablets seized in 1994; 227,199 tablets in 1995; 155,000
tablets in 1996; 35,000 in 1997; and 56,000 in 1998).
150Letter from Stephen H. Greene, DEA Deputy Administrator, to Phillip R. Lee, ASH, DHHS (Mar. 26, 1996), published in
the appendix of New International Threat of \Date-Rape Drug" Tracking, supra note 34, at 50 - 84. In a contemporaneous
report, the Congress that passed the CSA stated that potential for abuse includes any or all of the following four elements: (1)
evidence that individuals are taking the drug in amounts that create a hazard to their health or the safety of the community;
(2) diversion from legitimate channels; (3) self-administration of the drug without medical supervision; and (4) evidence that
the drug in question is so related in its action to another drug or drugs that it is likely that it will have the same abuse potential.
See H.R. Rep. No. 91-1444 (1970). As part of its recommendation to reschedule unitrazepam in schedule I, DEA concluded
that unitrazepam had a high potential for abuse based on the rst three factors. New International Threat of \Date-Rape
Drug" Tracking (letter from Stephen H. Greene to Phillip R. Lee), supra note 34, at 83 { 84.
151United Nations Convention on Psychotropic Substances, Feb. 21, 1971, 10 I.L.M. 261. See also Date Rape Drugs (prepared
statement of Terrance W. Woodworth, Drug Enforcement Agency), supra note 110, at 64; Date Rape Drugs (prepared statement
of Nicholas Reuter), supra note 110, at 71.
152DEA did so by rst publishing a notice in the Federal Register on August 1, 1984, giving all interested parties until August
31, 1984 to submit any comments on the proposal to add the twenty-one benzodiazepines to schedule IV. 49 Fed. Reg. 30748
(1984). When no comments or objections were received, the Attorney General added all twenty-one benzodiazepines to schedule
IV pursuant to the authority granted to him by the CSA.
153New International Threat of \Date-Rape Drug" Tracking (prepared statement of Robert B. Armstrong, Homann-La
Roche), supra note 34, at 43. In response to a senator's question of why Homann-La Roche had never sought to market
Rohypnol in the U.S., a company representative suggested that the decision was \primarily because of the competitive nature"
26On July 16, 1996, a U.S. Senate subcommittee held the rst Congressional hearing on Rohypnol, under the
title of \New International Threat of `Date-Rape Drug' Tracking."154 The Senators and those testifying
at this hearing spent much of their time discussing whether unitrazepam should be rescheduled under the
CSA.155 By this time, several legislators were indeed calling for the rescheduling of Rohypnol.156 At the
Senate hearing, Homann-La Roche opposed such an action, arguing:
The pharmacologic properties originally used to put unitrazepam in Schedule IV
have not changed, and there is no scientic or medical basis for rescheduling. Placing a
legitimate prescription pharmaceutical in the same category as LSD and narcotics including
heroin, is totally inappropriate. It ignores the worldwide use of this medication and has the
potential to penalize patients for whom it has been prescribed.
Most important, however, rescheduling as a means of addressing the problem would be
ineectual because schedules do not penalize criminals for sexual assault, and it ignores
other drugs also used to commit sexual assault. We know that other substances are being
misused in a manner similar to what has been reported to be associated with Rohypnol.
Moreover, I doubt drug abusers know the schedule of drugs. They do know the penalties of
the laws that are being enforced.157
Eventually Homann-La Roche's argument prevailed, and on October 4, 1996, Congress passed a law that did
not reschedule Rohypnol. Instead, the Drug-Induced Rape Prevention Act of 1996158 (1) attached schedule I
penalties to the tracking of unitrazepam,159 (2) created a new penalty of up to three years' imprisonment
of sleeping pills. New International Threat of \Date-Rape Drug" Tracking (testimony of Robert B. Armstrong, Homann-La
Roche), supra note 34, at 48.
154See New International Threat of \Date-Rape Drug" Tracking, supra note 34. Senator Joseph R. Biden, Jr., warned
about the dangers of Rohypnol before this hearing, when he authored a report in December 1995 that contained a chapter
titled \Rohypnol and Ketamine: New Drugs, New Dangers." See Facing the Future , supra note 33, at 49 { 73. Testifying
at the 1996 hearing were: Dr. Robert B. Armstrong, Homann-La Roche; Sen. Joseph R. Biden, Jr.; Lisa Celestin and Joy
Diliello, survivors of drug-facilitated rape; Maria Herrera, U.S. Customs; Daniel Redding, friend of a survivor; Det. Sgt. David
Robshaw, Broward County Sheri's Oce, Florida; Hon. Gerald Solomon, and; Terrance W. Woodworth, DEA. The appendix
included: Prepared Statement of Sen. Snowe; DEA Letter to HHS Requesting the Rescheduling of Flunitrazepam; Prepared
Statement of Monica M. Hofheinz, Assistant State Attorney and Executive Ocer, Florida; Prepared Statement of Robert
Nichols, Assistant State Attorney, Florida; and Date-Rape Drug: \Monster" Drug Soon to be on Same List as LSC, Heroin,
USA Today.
155See New International Threat of \Date-Rape Drug" Tracking, supra note 34.
156For instance, on March 14, 1996, Senator Biden introduced \A bill to provide for the rescheduling of unitrazepam into
schedule I of the Controlled Substances Act, and for other purposes." S. 1609, 104th Cong. (1996). On June 25, 1996,
Representative Schumer introduced \A bill to reduce violent crime by juvenile oenders," which moved Rohypnol to schedule
II. H.R. 3698, 104th Cong. (1996).
158Pub. L. No. 104-305, 110 Stat. 3087 (codied in scattered sections of 21 U.S.C. and 28 U.S.C.) (1999).
159Schedule I penalties generally include imprisonment up to twenty years for individuals who knowingly or intentionally
manufacture, distribute, or dispense one gram of a drug, or up to ve years for thirty milligrams. See Controlled Substances
27and/or a ne for simple possession of Rohypnol, (3) directed the U.S. Sentencing Commission to review and
amend the sentencing guidelines involving unitrazepam so that the guidelines reect the serious nature of
the drug, (4) authorized the Attorney General to create and distribute educational material for police ocers
regarding drug-facilitated sexual assaults, (5) ordered the DEA to study the appropriateness of rescheduling
Rohypnol and to submit a report on this study within six months, and (6) provided penalties of up to
twenty years imprisonment and nes for persons who intend to commit a crime of violence (including rape)
by distributing a controlled substance to another person without that individual's knowledge.160
During the debate leading up to the passage of this Act, several legislators accused many of their colleagues
of caving into the pressure of Homan-La Roche's lobbying eorts.161 Those in favor of moving Rohypnol
to schedule I argued that this action was important for several reasons. Senator Biden explained three of
these reasons in a oor speech, stating: (1) federal rescheduling would trigger increases in state drug law
schedules, which is vitally important because ninety-ve percent of all drug cases are prosecuted by the
states; (2) federal rescheduling to schedule I would trigger the toughest federal penalties; and (3) federal
Act, 21 U.S.C. x 841 (1999). This provision of the Act means that the penalties for Rohypnol abuse are the same as those for
heroin and LSD.
160Pub. L. No. 104-305, 110 Stat. 307 (codied in scattered sections of 21 U.S.C. and 28 U.S.C.) (1999).
161See, e.g., 142 Cong. Rec. E 1,757 (1996) (Statement of Hon. Schroeder) (\Why, you might ask, would anyone oppose
the rescheduling of a dangerous drug with no legitimate purpose in the United States and which has been used to facilitate the
rape of numerous young women, including many minors? Why would anyone argue for lenient treatment of a drug that has
been banned by the FDA and declared dangerous by the DEA? Because Homan-LaRoche [sic], the pharmaceutical company
that manufacturers Rohypnol and which sells the drug in 64 countries, has worked very hard to see the rescheduling provision
dropped. Homan-LaRoche [sic] stands to lose $100 million if Rohypnol is rescheduled because sales in other countries tend
to go down when the United States decides a drug is so dangerous it belongs on Schedule I.); 142 Cong. Rec. 11,124 (1996)
(statement of Hon. Schumer) (\[T]he bill before us is a watered down version of what the full Judiciary Committee approved
just last week. At that time, the committee voted to raise the drug's classication from what is known as schedule four...
to schedule one.... Somehow, between then and today, the majority was persuaded to weaken this bill, and to take out the
rescheduling provision. There is no way to describe this but a cave in to the demands of the pharmaceutical industry. I regret
that the majority backed down in the face of heavy, behind-the-scenes lobbying and brought this weak measure to the oor.");
142 Cong. Rec. 11,124 (statement of Hon. Jackson-Lee) (\this drug today remains a schedule IV drug, not because anyone
actually believes it is safe as the other schedule IV drugs like Valium, but because a drug company has successfully lobbied, to
the detriment of women and girls across the country); 142 Cong. Rec. 12,378 (1996) (statement of Sen. Biden) (\This delay
has the potential of leaving more children in danger. But, this is the reality of the situation we face because of one simple reason
{ a huge, foreign company that manufactures Rohypnol does not want America to reschedule their drug, even thought this
company does not { indeed cannot { sell this drug in America. It is just as simple as that, because a company is afraid of losing
some money, the eort to bring the maximum power of Federal law against the date rape drug has been defeated."). Between
January and June 1996, Homann-La Roche spent $130,000 on outside lobbying eorts that mainly focused on Rohypnol, and
$540,000 on in-house lobbying costs. Glaxo $3 Mil. Lobbying Budget in First Half of 1996 Includes Zantac Patent, F-D-C
Rep. (\The Pink Sheet"), Oct. 7, 1996, at 14.
28rescheduling had been eective in the past at curbing drug epidemics.162 Those on the other side of the
debate responded that schedule I was inappropriate for Rohypnol. For instance, Senator Hatch argued:
A unilateral eort on the part of the United States to reschedule the drug to the category
of \no medical use" could negatively aect the legitimate access to this drug oversees....
The regulations and controls placed on schedule I substances... eectively remove these
substances from the health care market.
The schedule I standards clearly do not apply to Rohypnol, a member of the ben-
zodiazepene [sic] class, which generally falls within the less restrictive schedule IV. Congres-
sional rescheduling { an action seldom taken { of this drug would indicate to other countries
that the United States believes there is no medical use for Rohypnol. In fact, there are
legitimate medical uses for Rohypnol. So, too, are there legitimate medical uses of many
other drugs not currently approved for sale in the United States. To make any medically
accepted drug a schedule I substance because it is being used illegally would be a troubling
precedent for our Nation's health care system. What drugs would be next? What other
drugs will be put beyond the reach of doctors and their patients because Congress chose to
act hastily?163
As noted above, Senator Hatch's view prevailed, and Rohypnol remained a schedule IV drug.164
Several actions stemmed from the Drug-Induced Rape Prevention Act. On May 1, 1997, the U.S. Sentencing
Commission submitted to Congress several amendments to the sentencing guidelines, one of which placed
unitrazepam in the guideline's drug quantity table to reect the increased penalties dictated by the Act.165
162142 Cong. Rec. 12,378 (1996) (statement of Sen. Biden). Senator Biden noted that after both Quaaludes and anabolic
steroids were rescheduled, their use greatly decreased. Id. Elsewhere, Senator Biden cites the statistic that in 1984, Quaaludes
were responsible for one in every one hundred drug emergency department cases. Then it was rescheduled in 1985, and in that
year the number dropped to one in every two hundred episodes. Since 1989, less than one in every ve hundred emergency
department cases involves Quaaludes. Facing the Future , supra note 33, at 72.
164Time magazine summarized the attempt to schedule Rohypnol as follows:
[T]he Rohypnol-controlling part of the legislation died under pharmaceutical-industry pressure. The industry, whose political
action committees last year donated $2.1 million to Republican candidates and $714,000 to Democrats, doesn't want the
added administrative burdens and federal oversight that come with scheduling a drug as a controlled substance.... Each unit
of a scheduled drug must be scrupulously accounted for, and some doctors won't prescribe drugs stigmatized by that heavy
designation.... [T]he industry's supporters in Congress are loath to change industry-friendly precedent, which allows drugs to
be scheduled only after lengthy administrative review.
Cloud, supra note 82.
165See U.S. Sentencing Guidelines Manual App. C, cmt. 556 (2000) (\This amendment implements the directive to the
Commission in the Drug-Induced Rape Prevention and Punishment Act of 1996.... This amendment reects the increases
in statutory maximum penalties for oenses involving tracking and simple possession, respectively, of unitrazepam. In
addition, the amendment contains a cross reference to cover the new oense created under this Act involving the distribution
of a controlled substance to an individual in order to commit a crime of violence against that individual. The eective date of
this amendment is November 1, 1997.").
29In addition, as required by the Act, DEA submitted a report to Congress regarding the rescheduling of
Rohypnol.166 This report stated that in January 1997, after completing its scientic and medical evaluation,
DHHS had provided its scheduling recommendation to DEA. DHHS recommended that unitrazepam re-
main in schedule IV, because its abuse potential did not dier from those of the other BZs, making schedule
IV the most appropriate level of control.167 DHHS's recommendation forced DEA to conclude that it did
not have sucient grounds to reschedule Rohypnol administratively, but in its report DEA conrmed its
support for legislative rescheduling.168 Despite some legislators' further attempts to reschedule the drug
legislatively,169 Rohypnol remains in schedule IV today.170
In December 1997, Attorney General Janet Reno directed DOJ to quantify the problem of drug-facilitated
rape.171 The DOJ Drug-Facilitated Rape Working Group was formed, and on June 26, 1998, completed its
report, much of which is cited in this paper.172 The Attorney General also collaborated with the Ameri-
166Controlled and Uncontrolled Substances Used to Commit Date Rape (prepared statement of John J. King), supra note 24,
at 51.
167See id., at 51; Date Rape Drugs (prepared statement of Terrance W. Woodworth), supra note 110, at 60. Part of DHHS's
recommendation, excerpted in a DOJ report, stated:
The Department concludes that the pre-clinical and clinical abuse liability research ndings and the actual abuse of u-
nitrazepam does not signicantly distinguish it from other benzodiazepine [sic] currently determined by the Department to
have a low abuse liability and controlled in Schedule IV. Furthermore, the same science suggests that the abuse liability of
unitrazepam is signicantly less than that of the Schedule II barbiturates. Thus, the abuse potential of this drug, based on the
factors applied by the Department, is consistent with control under Schedule IV. However, the Department has also concluded
that the drug has no accepted medical use in treatment in the United States, a nding that is consistent with control under
Schedule I. Under these circumstances, the Department recommends that there be no change in the current scheduling of this
drug substance under Schedule IV of the CSA.
NIJ, A Report to Attorney General, supra note 15, at 36.
168See Controlled and Uncontrolled Substances Used to Commit Date Rape (prepared statement of John J. King), supra note
24, at 51 { 52. In his testimony, DEA Deputy Assistant Administrator John H. King stated, \if I had my druthers, I would put
them both [Rohypnol and GHB] in Schedule." Controlled and Uncontrolled Substances Used to Commit Date Rape (testimony
of John J. King), supra note 24, at 59.
169See, e.g., S. 51, 106th Cong. x 104 (1999) (Violence Against Women Act II introduced by Senator Biden including a
provision rescheduling unitrazepam to schedule I).
170In 1994, the World Health Organization recommended to the Commission on Narcotic Drugs that the control of uni-
trazepam should be changed to schedule III. In early 1995, the member countries of this Commission (which does not include
the U.S.) voted to move unitrazepam to schedule III of the Convention on Psychotropic Substances. When asked by a senator
why the United States had not made this move as well, a DEA representative responded that in the U.S. \there virtually is no
dierence between schedule III and IV as far as the regulatory provisions. It's only the penalties." New International Threat
of \Date-Rape Drug" Tracking (prepared statement of Terrance W. Woodworth,) supra note 34, at 25.
171NIJ, A Report to the Attorney General, supra note 15, at 1. The Working Group was composed of sta from several
agencies and oces, including: NIJ, DEA, Violence Against Women Act oce, Oce for Victims of Crimes, Oce of Consumer
Litigation, and Federal Bureau of Investigation. Id.
172Id. This report did not focus solely on Rohypnol, but instead examined several dierent drugs, including GHB and ketamine.
30can Prosecutors Research Institute of the National District Attorneys Association to produce a video and
training manual on prosecuting drug-facilitated rape.173 In December 1999, NIDA and four private partners
launched a national education and prevention campaign focusing on club drugs, including Rohypnol, GHB,
and ketamine.174 This initiative consists of a forty-percent increase in funding for research about club drugs,
and a multi-media public education strategy which includes a website to warn the public about the danger
of club drugs.175 In July 1997, DEA established Operation \Flashback," a special enforcement program
designed to deal exclusively with club drugs, including Rohypnol, GHB, and ketamine.176
Thus the federal government has pursued several dierent avenues in responding to the use of Rohypnol
to facilitate sexual assault. It increased the penalties for tracking and possessing Rohypnol, strengthened
its eorts to seize the drug and stop its importation, created a new crime of drugging someone with the
intent to commit violence, attempted to measure the problem, and developed prevention plans and education
initiatives for both the public and law enforcement.177
b.
GHB
173APRI, supra note, 12, at Preface; see also Videotape: The Prosecution of Rohypnol and GHB Related Sexual Assaults
(American Prosecutors Research Institute 1999).
174National Institute on Drug Abuse, Club Drugs Take Center Stage in New National Education and Prevention Initiative
by NIDA and National Partners (Press Release), Dec. 2, 1999, available at <http://165.112.78.61/MedAdv/99/NR-122.html>
(visited Mar. 30, 2001). NIDA's four partners are the American Academy of Child and Adolescent Psychiatry, the Community
Anti-Drug Coalitions of America, Join Together, and National Families in Action.
175Id. See www.clubdrugs.org (visited Mar. 30, 2001).
176See The Threat Posed by the Illegal Importation, Tracking and Use of Ecstasy and Other Club Drugs: Hearing Before
the House Subcomm. on Crime of the Comm. on the Judiciary, 106th Cong. (2000) (prepared statement of Lewis Rice,
Jr., Drug Enforcement Administration). Operation Flashback seeks to: (1) develop prosecutable cases against individuals and
organizations that manufacture and distribute club drugs; (2) develop intelligence links between domestic wholesale distributors
and the foreign source of supply; (3) identify, arrest, and prosecute violators at a high level of distribution; (4) establish and
coordinate an overall strategy for all domestic and foreign investigative eorts; and (5) identify the command and control
infrastructures of organizations that are distributing club drugs. Id.
177Note that the latter three responses apply to GHB and ketamine as well.
31As mentioned above, the federal government rst responded to GHB in 1990, before it was
known as a date-rape drug, when FDA banned the drug from being sold in the U.S.178 After
this announcement, the DOJ's Oce of Consumer Litigation (OCL) began prosecuting traf-
ckers of GHB under the Federal Food, Drug, and Cosmetic Act (FFDCA).179 DOJ's Civil
Resource Manual explains the legal basis for these prosecutions.180 GHB is a drug because the
claims associated with it meet the drug denition in the FFDCA;181 these claims allege that
GHB aects growth hormones, promotes sleep, has anabolic and psychoactive properties, and
stimulates sexual desire.182 GHB is considered a misbranded drug because in all of the cases
in which it has been distributed the labeling has been decient.183 It violates the FFDCA
to: (1) distribute misbranded GHB in interstate commerce;184 (2) receive an ingredient in
interstate commerce and use it to manufacture and sell misbranded GHB;185 (3) receive mis-
branded GHB from interstate commerce and oer it for sale;186 or (4) manufacture GHB for
commercial distribution without registering to do so.187 If done with the intent to defraud,
these violations are felonies.188 FDA's Oce of Criminal Investigations (OCI) investigated
these crimes, focusing on large scale interstate manufacturers and distributors, including In-
178See supra note 58 and accompanying text.
179Date Rape Drugs (prepared statement of Patricia L. Maher, Department of Justice), supra note 110, at 56. The OCL,
which is part of the Civil Division of the DOJ, handles, among other matters, civil and criminal cases brought under the Federal
Food, Drug, and Cosmetic Act. See id.
180Department of Justice, GHB FDCA Violations, Civil Resource Manual, x 16 (1999), available at
<www.usdoj.gov/usao/eousa/foia reading room/usam/title4/civ00016.htm> (visited Mar. 30, 2001).
181See 21 U.S.C. x 321(g)(1)(C).
182Department of Justice, GHB FDCA Violations, supra note 180.
183Id. The Civil Resource Manual lists the provisions under which GHB labeling has been decient: 21 U.S.C. x 352(b)(1)
(label does not contain the name and place of business of manufacturer, packer, or distributor), x 352(b)(2) (label does not
contain accurate statement of quantity of contents), x 352(e) (label does not contain the established name of the drugs), and
x352(f) (label does not contain adequate directions for use and warnings). Because adequate directions and warnings can most
likely not be written for GHB, the Civil Resource Manual concludes that GHB will remain misbranded.
184See 21 U.S.C. x 331(a).
185See 21 U.S.C. x 331(k).
186See 21 U.S.C. x 331(c).
187See 21 U.S.C. xx 360 and 331(p).
188Department of Justice, Civil Resource Manual, supra note 180. The Civil Resource Manual provides examples of
charges for GHB felony and misdemeanor cases. Department of Justice, Civil Resource Manual, x 17 (1999), available at
<www.usdoj.gov/usao/eousa/foia reading room/usam/title4/civ00017.htm> (visited Mar. 30, 2001).
32ternet web site vendors.189 OCL prosecuted its rst GHB case under the FFDCA in 1992.190
By May of 1999, OCL had successfully prosecuted over thirty people for GHB violations, and
had many cases pending.191
The eorts of the OCI and OCL seemed insucient to many legislators and activists, however,
who thought that in light of the high prevalence of GHB misuse192 DEA needed to be involved
in investigating these cases.193 Because GHB was not a scheduled drug, DEA had no jurisdic-
tion over the drug's illegal use.194 In an attempt to remedy this situation, in September 1997,
DEA sent its scheduling review of GHB to DHHS and requested that agency's scientic and
medical evaluation and recommendation.195 Furthermore, in 1997 and 1998, several legislators
introduced bills to make GHB a scheduled drug.196 On July 30, 1998, the House Subcommit-
tee on Crime held Congress's second hearing on drug-facilitated rape, titled \Controlled and
Uncontrolled Substances Used to Commit Date Rape."197 While during the 1996 hearing only
189Date Rape Drugs (prepared statement of Nicholas Reuter), supra note 110, at 72. In addition to investigating GHB
manufacturing and distributing cases, OCI also worked with DOJ and Center for Drug Evaluation and Research (CDER) to
develop procedures for safe handling and processing of GHB evidence and to maintain a list of scientic experts for court
testimony, and provided assistance to local and state police departments conducting GHB investigations. See id.
190Date Rape Drugs (prepared statement of Patricia L. Maher), supra note 110, at 57. This prosecution involved many
defendants who, led by anabolic steroid dealer Mark Thierman, sold GHB by mail order throughout the country and made
hundreds of thousands of dollars. Eleven were convicted of charges including conspiracy, manufacturing and distributing
misbranded and adulterated drugs with the intent to defraud and mislead, and operating an unregistered drug manufacturing
facility with the intent to defraud. Thierman was sentenced to forty-nine months of incarceration. Id. at 56 { 57.
191Id. at 57.
192By February 1997, the drug had become so popular that FDA issued its second public warning on the dangers of
GHB, stating that although promoters of the drug claim it is a legal drug, it is in fact illegal to produce or sell the
drug. Food and Drug Administration, FDA Re-Issues Warning on GHB (FDA Talk Paper), Feb. 18, 1997, available at <
http://www.fda.gov/bbs/topics/answers/ans00787.html> (visited Mar. 27, 2001).
193See Date Rape Drugs (prepared statement of Trinka Porrata), supra note 110, at 32.
194Id.
195Date Rape Drugs (prepared statement of Terrance W. Woodworth), supra note 110, at 62. DEA could not use its \emer-
gency" scheduling power under the CSA because GHB was being evaluated as part of a DHHS approved research program. Id.
at 60.
196See, e.g., H. R. 1530, 105th Cong. (1997) (legislation introduced by Hon. Sheila Jackson-Lee to schedule GHB in Schedule
I); H. R. 1726, 105th Cong. (1997) (legislation introduced by Hon. Bart Stupak to schedule GHB in Schedule III).
197See Controlled and Uncontrolled Substances Used to Commit Date Rape, supra note 24. Those participating were: Dr.
Joye M. Carter, Medical Examiner; Paul Doering, Professor of Pharmacy; Raul Farias, uncle of a GHB victim; John J. King,
III, DEA; and Det. Michael Stevens, Orlando, FL Police Department. The following materials were submitted for the record:
an article by Trinka Porrata; a letter from Orphan Medical, Inc. to Subcommittee on Crime; letter from FDA's Orphan
Products Development to Orphan Medical, Inc.; letter from FDA's Orphan Products Development to Senate Ways and Means
Committee; letter from Mali A. Einen (a narcoleptic patient) to Subcommittee on Crime; letter from National Organization
for Rare Disorders to Subcommittee on Crime; letter from National Sleep Foundation to Subcommittee on Crime.
33one participant mentioned GHB,198 the drug was the focus of the 1998 hearing. In addition to
providing legislators with information about the drug, the hearing focused on nding a way
to control the illegal use of the drug without destroying its potential of becoming a successful
narcolepsy treatment. Orphan Medical, Inc., the National Organization for Rare Disorders,
Inc. (NORD), and the National Sleep Foundation argued that placing GHB in schedule I or
II would eectively force Orphan Medical to stop developing the drug.199 NORD explained:
We truly believe that scheduling GHB as a Schedule I or II controlled substance would be
an insurmountable obstacle for a small drug manufacturer and a nightmare for patients and
doctors.... the security, registration, reporting, and other requirements a company would
have to meet to manufacture the drug, or even to continue ongoing research on it, would
be so costly as to make the investment prohibitive.... Moreover, such restrictions would
make the cost of the drug unaordable to many narcolepsy patients, and it would encourage
doctors not to prescribe it.
... if [Orphan Medical] does not complete its development of the drug, or does not accomplish
the costly and dicult manufacturing requirements, narcolepsy patients will never have
access to this treatment.
There is also another consequence that is equally troubling. That is other companies will
watch this disaster and learn that even if FDA `recruits' them to develop an orphan drug,
and even if they are well along in the development process, their investment or resources
may be at risk. If one arm of the government encourages you to develop a product, while
another discourages you without regard to the valid medical need for the product, this could
be disastrous for the future of all orphan drug development.
... The rst and most important step that Congress can take is to regulate the Internet and
get the formula for GHB o of the World Wide Web! None of the crimes involving GHB
have been caused by the medical version of the drug. They have all been caused by criminal
amateurs who make the compound themselves. To make GHB a Schedule I drug would
be tantamount to scheduling Aspirin as Schedule I simply because some people (7,000 per
year) die from Aspirin.200
Orphan Medical suggested that Congress should: (1) place GHB in schedule IV, which would make the
crime of using a controlled substance to commit violence applicable to GHB; and (2) should attach schedule
I penalties for anyone convicted of possessing, distributing and manufacturing GHB or its analogs illegally,
198See New International Threat of \Date-Rape Drug" Tracking (prepared statement of Robert Nichols), supra note 34, at
90.
199See Controlled and Uncontrolled Substances Used to Commit Date Rape, supra note 24, at 63 { 71.
34as Congress did with respect to Rohypnol in its 1996 legislation.201
Proponents of placing GHB in schedule I contended that this action would most eectively curb the illegal
uses of the drug and would not disturb narcolepsy treatment research. A DEA representative explained that
placing a drug in schedule I is better than attaching schedule I penalties to it because the public and law
enforcement ocials perceive schedule I drugs as the most dangerous, which leads them to pay the most
attention to and be the most vary of schedule I drugs.202 In addition, as discussed above, because most
states' scheduling systems are triggered by changes in the federal system, a federal action placing GHB in
schedule I would prompt most states to do the same.203 DEA also concluded that because the schedule I
additional regulatory requirements are \minimal" and other drugs had been successfully developed while
under this schedule, \Schedule I controls should not prevent or preclude the development of GHB as a new
pharmaceutical product.... Schedule I control should not prevent any patient population in the United States
from receiving adequate medical treatment."204 Thus DEA sharply disagreed with Orphan Medical and its
supporters about the eect on narcolepsy research of placing GHB in schedule I.
By March 1999, GHB still had not been scheduled, legislatively or administratively. On March 11, the House
Subcommittee on Oversight and Investigations held Congress' third hearing regarding date-rape drugs.205
While the past two hearings had been relatively non-partisan and cooperative, it appears that as the problem
kept growing and no action on GHB was taken, some legislators decided to use this hearing as a vehicle
201Controlled and Uncontrolled Substances Used to Commit Date Rape (letter from Orphan Medical to Subcommittee on
Crime), supra note 24, at 63.
202See Controlled and Uncontrolled Substances Used to Commit Date Rape (prepared statement of John J. King), supra
note 24, at 55; Controlled and Uncontrolled Substances Used to Commit Date Rape (letter from Drug Enforcement Agency to
Subcommittee on Crime), supra note 24, at 60.
203Controlled and Uncontrolled Substances Used to Commit Date Rape (prepared statement of John J. King), supra note 24,
at 55.
204Controlled and Uncontrolled Substances Used to Commit Date Rape (letter from Drug Enforcement Agency to Subcom-
mittee on Crime), supra note 24, at 61.
205Date Rape Drugs, supra note 110. Those testifying included: Felix Adatsi, Toxicologist, Michigan State Police; Paul Bane,
Maryland State Police; Patti Engel, Orphan Medical, Inc.; Det. G. Mark Faistenhammer, Grosse Ile Police Department; Hon.
Sheila Jackson-Lee; Patricia L. Maher, DOJ; Trinka D. Porrata, designer drug consultant; Candace Pruett, victim; Nicholas
Reuter, FDA; Terrence W. Woodworth, DEA; Stephen Zukin, NIDA. Materials submitted for the record included a prepared
statement of Abbey S. Meyers, NORD, and a letter to the Subcommittee on Oversight and Investigations from DHHS.
35to place blame on members of the opposite political party or on the executive branch. Several Democratic
legislators accused the Republican majority of preventing legislative action for over two years, with one
representative suggesting that a sixteen-year-old girl who died after she was secretly given GHB might had
been saved but for Republican inaction.206 Several Republican legislators spent much of their time grilling
the FDA representative, Dr. Nicholas Reuter, on why it was taking so much time for DHHS to make its
nal scheduling recommendation to DEA, which as mentioned above had requested a review in September
1997.207 Dr. Reuter responded that although on average DHHS completes its scheduling reviews within eight
to ten months, the review of GHB was taking longer due to GHB's potential as a narcolepsy treatment.208
He explained that the need to protect the public from drugs may sometimes conict with the benecial uses
of the drugs to a smaller segment of the public, creating a \tension in the scheduling process."209 Democratic
representatives defended the FDA by pointing out that the administrative scheduling process is designed to
take a signicant amount of time, whereas Congress has the ability to act quickly.210
In addition to the accusations of blame, this hearing also raised another issue: how to deal with GHB's
analogues. By this time, reports of GBL and BD abuse were increasing.211 The DEA representative explained
to the Subcommittee that if GHB were placed in schedule I or II, then GBL could be considered an analog
and treated as if it were a controlled substance in schedule I.212 But GBL would only meet the denition of
206See Date Rape Drugs (opening statement of Hon. Bart Stupak), supra note 110, at 4..
207See Date Rape Drugs, supra note 110, at 78 { 83; Date Rape Drugs (opening statements of Hon. Richard Burr and Hon.
Ed Whiteld), supra note 110, at 8, 11.
208Date Rape Drugs (prepared statement of Nicholas Reuter), supra note 110, at 73.
209Id. at 70.
210See, e.g., Date Rape Drugs (opening statement of Hon. Ron Klink) (prepared statement of Hon. Henry A. Waxman),
supra note 110, at 9, 12.
211These reports led FDA to issue a warning about GHB, GBL, and BD, which stated: \Swallowing any of these ingredients
may make you extremely sick and may even kill you." See Letter from Janet Woodcock, CDER, to \All Health Care Professional
Organizations," (June 15, 1999); FDA, Dangerous: Food and Drug Administration Says Dietary Supplements containing BD,
GBL, and GHB Can Kill You! (yer enclosed with letter), available at <http://www.fda.gov/cder/graphics/ghb.gif> (visited
Mar. 27, 2001).
212See Date Rape Drugs (prepared statement of Terrance W. Woodworth), supra note 110, at 86. DEA explains how the
analogue law works:
A new class of substances was created by the Anti-Drug Abuse Act of 1986. Controlled substance analogues
are substances which are not controlled substances, but may be found in the illicit trac. They are structurally
or pharmacologically similar to Schedule I or II controlled substances and have no legitimate medical use. A
substance which meets the denition of a controlled substance analogue and is intended for human consumption
36an analog if the drug was represented to be intended for human consumption, allowing smart drug dealers
to simply sell the drug without explaining its use.213 Therefore, DEA recommended that GBL be controlled
separately under the CSA as a List I chemical.214
On May 19, 1999, DHHS recommended a dual scheduling, concluding that GHB in general should be placed
in schedule I, with the exception that any GHB drug product studied under an investigational new drug
(IND) exemption should be controlled by schedule III.215 By the end of 1999, DEA had not taken the nal
steps necessary to administratively schedule GHB. Regarding this delay, Senator Orrin Hatch in a oor
speech stated:
is treated under the CSA as if it were a controlled substance in Schedule I.
Drug Enforcement Administration, Controlled Substance Analogues <http://www.dea.gov/concern/abuse/chap1/control/analog.htm>
(visited Mar. 27, 2001).
213See Date Rape Drugs (prepared statement of Terrance W. Woodworth), supra note 110, at 86. See Controlled Substances
Act, 21 U.S.C. 802(32) (1999) (dening \controlled substance analogue").
214Id. at 87. In addition to schedules I through V for substances, the CSA also created two categories { List I and List II
{ for chemicals used to manufacture controlled substances. Those chemicals in List I chemicals are considered \important" in
the manufacturing of controlled substances. 21 U.S.C. 802(34). Registration, recordkeeping, and reporting requirements apply
to List I and List II chemicals. See Date Rape Drugs (prepared statement of Terrance W. Woodworth), supra note 110, at 87.
215Letter from David Satcher, Assistant Secretary for Health and Surgeon General, DHHS, to Donnie R. Marshall, Deputy
Administrator, DEA (May 19, 1999), printed in Schedules of Controlled Substances: Addition of Gamma-Hydroxybutyric
Acid to Schedule I, 65 Fed. Reg. 13,235 (2000) (to be codied at 21 C.F.R. pts. 1301 and 1308). A brief ex-
planation of the drug approval process is explained so the reader will understand the reference to an IND in DHHS's
scheduling recommendation. Three major stages comprise the drug approval process: (1) preclinical research; (2) clini-
cal research to determine eectiveness and side eects; and (3) FDA evaluation and approval of a new drug application
(NDA). See Center for Drug Evaluation and Research, Drug Approval Application Process (last modied Nov. 15, 2000)
<http://www.fda.gov/cder/regulatory/applications/default.htm#Introduction>. At the second stage, an IND exemption is
necessary because federal law requires that a drug be the subject of an approved marketing application before it can be trans-
ported or distributed across state lines. Because a company will most likely want to ship the investigational drug to clinical
investigators in many states, it must obtain an exemption from that legal requirement. The IND is the means through which
the company obtains this exemption from the FDA. Center for Drug Evaluation and Research, Investigational New Drug Ap-
plication Process (last modied Feb. 26, 2001) <http://www.fda.gov/cder/regulatory/applications/ind page 1.htm>. A special
kind of IND { a treatment IND { may be submitted for drugs showing promise in clinical testing for serious conditions while
the nal clinical work is conducted and the FDA review takes place. See Treatment Use of An Investigational New Drug, 21
C.F.R. x 312.34 (1999). Once the clinical research nears completion, the company submits a NDA to FDA for nal approval.
FDA allowed Orphan Medical to proceed with its treatment IND on December 16, 1998. FDA, Treatment Investigational New
Drugs (IND) Allowed to Proceed (last modied Sept. 24, 1999) <http://www.fda.gov/oashi/patrep/treatind.html>. Orphan
Medical led its NDA on October 10, 2000, and the FDA gave it priority review status. Orphan Medical Xyrem, F-D-C Rep.
(\The Pink Sheet"), Jan. 22, 2001, at 32.
37Although there have been reports of substantial GHB abuse for several years now,
I do not know why the Attorney General and the Secretary of Health and Human Services
have been unable to resolve the matters that have precluded this drug from being scheduled
through normal procedures under the Controlled Substances Act. I don't know why it took
until September of 1997 for the DEA to request FDA to analyze the medical and scientic
matters relating to GHB. I don't know why it took until May 19, 1999 to get a response
to this request. I don't know why DEA has not acted in the last six months to bring this
matter to a conclusion through administrative means. It should not take an act of Congress
to schedule a dangerous drug under the Controlled Substances Act.
I do know that part of the unjustiable delay in the scheduling of GHB stemmed
from the fact that there is a dierence of opinion between DEA and FDA about how to
schedule this drug. But that answer is not good enough....
... This situation points out that a signicant breakdown in the system has occurred
with respect to the scheduling of GHB. It behooves the Congress to deliberate more over
ways to make the key agencies, DEA and FDA, be more responsive in the future, rather
than be force to do their jobs for them. The lesson GHB should not be to teach the agencies
to wait for Congressional action whenever the bureaucracy cannot act.216
Finally, on January 31, 2000, Congress passed the Hillory J. Farias and Samantha Reid Date-Rape Drug
Prohibition Act of 1999, which President Clinton signed into law on February 22, 2000.217 This Act directs
the Attorney General to place GHB in schedule I, but to treat it as a schedule III drug when the drug is
manufactured, distributed, or possessed in accordance with an IND.218 The Act also states that if GHB
is ever approved as a new drug, the new product should be placed in schedule III, although the Attorney
General may impose additional record keeping requirements on it and any misuse of it will trigger schedule
I penalties.219 The Act adds GBL to the List I chemical list, and claries that GBL may also be considered
an analogue of GHB when intended for human consumption.220
217Pub. L. No. 106-172, 114 Stat. 7 (codied in scattered sections of 21 U.S.C.) (June 2000 Supp.). Hillory J. Farias was a
seventeen-year-old high school student who died in August 1997 after someone slipped GHB into her soda. She left a dance
club complaining of a headache, went to bed, and was found unconscious by her grandmother the next morning. See 145 Cong.
Rec. 9,866 (statement of Hon. Jackson-Lee); Controlled and Uncontrolled Substances Used to Commit Date Rape (testimony
of Raul Farias), supra note 24, at 9 { 11; Cindy Horswell, La Porte Teen's Death Found to Be Homicide; `Date Rape' Drug in
Body, Houston Chron., Sept. 10, 1996, at 17. Samantha Reid, a fteen-year-old girl, was killed in January 1999 when four
young men decided to slip GHB into her Mountain Dew as well as into the drinks of her two girl friends. For the complete
story of this tragic event, see the two-part article by Jodi S. Cohen, Trendy Drug Shatters Hopes, Dreams, Innocence, Detroit
News, Dec. 5, 1999, at A1 and GHB Slips Into Families' Lives, Now Won't Let Go, Detroit News, Dec. 6, 1999, at A1.
218Pub. L. No. 106-172, 114 Stat. 7 (codied in scattered sections of 21 U.S.C.) (June 2000 Supp.).
219Id.
220Id.
38In addition, the Act orders the Attorney General to: (1) develop model protocols, training materials, forensic
eld tests, and coordination mechanism for investigations and prosecutions relating to GHB and other date-
rape and designer drugs; (2) establish a special unit in DEA for assessment of abuse and tracking of GHB,
unitrazepam, ketamine, and other designer drugs that have been used to facilitate rape; and (3) report to
Congress with the recommendations of the special unit.221 Finally, the Act directs the Secretary of DHHS
to develop a national awareness campaign on date-rape drugs and submit to Congress each year an annual
report regarding date-rape drugs.222
In complying with the Act, on March 13, 2000, and April 24, 2000, DEA ocially placed GHB in schedule I
(with the exception for Xyrem) and GBL in List I, respectively.223 DEA also established the Dangerous Drug
Unit, dedicating sta to focus solely on the issue of date-rape drugs and to create education programs and
track the use of date-rape drugs and precursors.224 As mentioned above, various other federal agencies have
also created training, education and prevention programs concerning GHB.225 Thus, as with its treatment
of Rohypnol, the federal government has undertaken a variety of responses to the problem of GHB-related
sexual assault.
c.
Ketamine
221Id.
222Id.
223Schedules of Controlled Substances: Addition of Gamma-Hydroxybutyric Acid to Schedule I, 65 Fed. Reg. 13,235 (2000)
(to be codied at 21 C.F.R. pt. 1301 and 1308); Placement of Gamma-Butyrolactone in List I of the Controlled Substances
Act, 65 Fed. Reg. 21,645 (2000) (to be codied at 21 C.F.R. pt. 1310).
224Telephone Interview with Marcia Lee, supra note 147.
225See supra notes 171 { 76 and accompanying text.
39The story of the federal response to ketamine is more simple than those of Rohypnol and GHB, for several
reasons: (1) DHHS and DEA were able to agree upon the appropriate schedule for the drug; (2) the
pharmaceutical industry supported the control; and (3) ketamine was never thought to be used as a date-rape
drug as often as GHB and Rohypnol were. In 1981 and 1986, DHHS recommended that ketamine be placed
in schedule III based on the pharmacological prole of the drug.226 In response to both recommendations,
DEA concluded that the incidence of actual abuse of ketamine, in combination with the drug's status as a
prescription drug with limited distribution, did not rise to the level necessitating control under the CSA.227
Thus during the 1980s and most of the 1990s, DEA did not have jurisdiction over ketamine cases. As
was the case with GHB, however, the FDA's OCI could investigate and DOJ's OCL could prosecute illegal
manufacturers and distributors of ketamine under the FFDCA.228
During the second half of the 1990s, various legislators introduced bills to schedule ketamine, often as part of
bills scheduling provisions scheduling Rohypnol and/or GHB.229 The increase in ketamine abuse during the
1990s prompted the DEA in April 1998 to request a review and scheduling recommendation from DHHS.230
DHHS responded quickly, and in December 1998 recommended that ketamine be placed in schedule III.231
On April 9, 1999, DEA published it proposal to place ketamine in schedule III,232 and on July 13, 1999,
published its nal rule making this placement.233 DEA received only ve comments in response to its
proposal, including four in favor from the American Animal Hospital Association, the American Veterinary
Medical Association, the American Association of Equine Practitioners, and a practicing veterinarian and
226See Date Rape Drugs (prepared statement of Terrance W. Woodworth), supra note 110, at 65.
227Id.
228See NIJ, A Report to the Attorney General, supra note 15, at 36. See supra notes 170 { 180 and accompanying text for
the explanation of how these prosecutions can take place under the FFDCA.
229See, e.g., S. 1609, 104th Cong. (1996) (Senator Biden's bill scheduling ketamine in schedule II and unitrazepam in schedule
I); H.R. 1530, 105th Cong. (1997) (Hon. Jackson-Lee's bill scheduling ketamine in schedule II and GHB in schedule I); H.R.
1821, 105th Cong. (1997) (Hon. Stupak's bill scheduling ketamine and GHB in schedule III); S. 1561, 106th Cong. (1999) (Sen.
Abraham's bill scheduling ketamine in schedule III and GHB in schedule I).
230See Date Rape Drugs (prepared statement of Terrance W. Woodworth), supra note 110, at 65.
231Id.
232Schedules of Controlled Substances: Proposed Placement of Ketamine into Schedule III, 64 Fed. Reg. 17,499 (1999).
233Schedules of Controlled Substances: Placement of Ketamine into Schedule III, 64 Fed. Reg. 37,673 (1999) (to be codied
in 21 C.F.R. pt. 1308).
40only one in opposition from a supplier of generic ketamine.234 This administrative action made it unnecessary
for Congress legislatively to schedule ketamine. The federal government's prevention, education, and training
initiatives involving GHB and Rohypnol have also focused on ketamine.235
3.
The State and Local Response
State governments have also responded to the increase in drug-facilitated rapes. Several have created new
crimes or amended their denitions of rape to deal with this problem, and most states have scheduled
Rohypnol, GHB, and ketamine at or above the corresponding federal schedule. States have also launched
public education campaigns and law enforcement trainings.
As of April 1, 2001, 49 states had scheduled Rohypnol and ketamine, and 47 states had scheduled GHB.236
Of those states scheduling Rohypnol, 38 (77.5%) placed it in the same schedule as the federal government
(schedule IV) while 11 (22.5%) placed it in schedule I. Of those states controlling GHB, 40 (85.1%) placed
GHB in schedule I, 3 (6.4%) in schedule II, 2 (4.3%) in schedule IV, and 2 (4.3%) in schedule III. Out of
the 40 states scheduling GHB in schedule 1, 20 made an exception for any FDA-approved GHB, which will
be placed in schedule III. Of the 49 states controlling ketamine,237 42 (87.5%) did so by placing the drug in
schedule III, 4 (8.3%) in schedule IV, and 2 (4.2%) in schedule I. Many of the states scheduled GHB and
234Id.
235See supra notes 171 { 76 and accompanying text.
236The schedule for each drug in each of the fty states is listed in Table I of the Appendix. The statistics described in this
paragraph are all derived from Table I.
237Although Vermont controls ketamine, it does not have separate schedules for drugs, but rather has one category called
\Regulated Drugs." Vermont was thus not included when calculating the percentages of how many states place ketamine into
each schedule.
41ketamine before the federal government did so. Several states also created specic crimes involving these
particular drugs, or provided for additional penalties for possessing or distributing these drugs.
In addition to scheduling Rohypnol, GHB, and ketamine, many states have amended their denitions of
sexual assault to include drug-facilitated rape,238 and some have created a separate oense or sentence for
drug-facilitated rape. 239 States have also engaged in education and awareness campaigns. For example,
on January 26, 1998, the Illinois Attorney General, State Police, and Coalition Against Sexual Assault
sponsored a meeting called the `Emergency Campus Summit on Date Rape Drugs," at which representatives
from rape crisis centers, medical facilities, and law enforcement agencies discussed ways to respond to the
use of date-rape drugs on college campuses.240 The participants devised dierent guidelines for those groups
who are often the rst to receive sexual assault reports { campus administrators and faculty, law enforcement
238See, e.g., Del. Code Ann. tit. 11, x 773 (2000) (dening one type of rape in the rst degree as sexual intercourse without
a victim's consent that is facilitated by unlawfully administering drugs); La. Rev. Stat. Ann. x 14:42.1 (2000) (dening one
type of forcible rape as sexual intercourse without a victim's consent when the victim is incapable of resisting or of understanding
the nature of the act because of stupor or abnormal condition of the mind produced by a drug administered by the oender
without the victim's knowledge); Me. Rev. Stat. Ann. tit. 17-A, x 253 (West 2000) (dening one type of gross sexual assault
as occurring when a person engages in a sexual act with another person and the oender has substantially impaired the victim's
power to appraise or control the oender's sexual acts by administering drugs to the victim); Mo. Rev. Stat. x 566.030 (1999)
(dening one type of forcible rape as having sexual intercourse with a victim after a substance is unknowingly administered
to the victim which renders the victim physically or mentally impaired and incapable of making giving informed consent to
sexual intercourse); Or. Rev. Stat. x 2907.02 (2000) (dening one type of rape as sexual conduct with another when, for
the purpose of preventing resistance, the oender substantially impairs the victim's judgment or control by administering any
drug to the victim surreptitiously or by force, threat of force, or deception); S.C. Code Ann. x 16-3-652 (2000) (dening one
type of criminal sexual conduct in the rst degree as occurring when the oender engages in sexual battery with the victim
and causes the victim, without consent, to become mentally incapacitated or physically helpless by administering or causing to
be administered a drug to the victim); Tex. Penal Code x 22.021 (2000) (dening one type of aggravated sexual assault as
occurring when an oender administers or provides unitrazepam or GHB to the victim of a sexual assault with the intent of
facilitating the commission of the crime); Utah Code Ann. x 76-5-406 (2000) (denes lack of consent of victim as occurring
when an oender intentionally impairs the power of the victim to appraise or control his or her conduct by administering any
substance without the victim's knowledge); Vt. Stat. Ann. tit. 12, x 3252 (2001) (dening one type of sexual assault as
occurring when a person engages in a sexual act with another persons after having substantially impaired the ability of the
victim to appraise or control his or her conduct by administering drugs without the knowledge or against the ill of the victim).
239See, e.g., Mass. Gen. Laws ch. 272, x 3 (2001) (punishing the crime of administering a drug to another person in order
to have sexual intercourse with that person with up to life imprisonment, with a minimum sentence of ten years); Miss. Code
Ann. x 97-3-65 (2001) (punishing the crime of administering a drug to a victim to have sexual intercourse with the victim
with up to life imprisonment); Nev. Rev. Stat. Ann. x 200.408 (2001) (punishing the crime of administration of controlled
substance to aid commission of crime of violence with a minimum of one year and a maximum of twenty years in state prison);
18 Pa. Cons. Stat. x2714 (2000) (dening \unauthorized administration of intoxicant" as a third degree felony when done
with the intent to commit sexual assault). For a slightly outdated analysis of which states' laws recognize drug-facilitated rape,
and in which way they do so, see NIJ, A Report to the Attorney General, supra note 15, at 37.
240See Illinois Attorney General Jim Ryan, Averting The Campus Date Rape Drug Crisis: Seven Solutions
for Colleges, Law Enforcement and Medical Professionals (1999 Campus Safety Summit Edition), available at
http://ag.state.il.us/program/drd/manual99.pdf (visited Mar. 25, 2001).
42personnel, and hospital and medical personnel.241 The summit also led to instructions on how to implement a
community task force to comply with the federal and state Campus Security Acts, as well as the development
of a campus education kit, training modules for students, and recommendations for police training, date
collection, and legislation.242 Some of the posters produced for the public education campaign included the
following: a beer can with the label reading \You know what's in your best friend's diary, how about her
beer?," a water bottle with the headline \Everything but the Rooes came from a pure glacial spring," and
a bottle cap with the question, \How would you like your margarita? Frozen, on the rocks or with rape?"243
While states have focused on scheduling drugs used to facilitate rape and educating the public about the
dangers of these drugs, local governments have been responsible for most of the prosecutions of these type
of cases. In March 2000, prosecutors in Wayne County, Michigan obtained convictions in the country's
rst manslaughter trial for poisoning by GHB.244 Three men were convicted of involuntary manslaughter
for slipping GHB into the soda of fteen-year-old Samantha Reid { one of the girls whose name appears
in the title of Congress' 1999 act.245 In the summer of 1997, a Los Angeles jury convicted Steven Michael
Hagemann and Danny Richard Bohannon { whose GHB-facilitated rapes are discussed in the introduction
to this paper { of many counts of rape and sexual assault and sentenced them to seventy-seven and nineteen
years in prison, respectively.246 A year later, in nearby Santa Monica, California, brothers George and Stefan
Spitzer { whose use of Rohypnol to rape women is also described in the introduction to this paper { were
sentenced to sixty years and thirty-seven years, respectively, for felonies including kidnapping, sodomy, rape,
241Id.
242Id.
243Pete Millard, National Ad Campaign Warns About Date-Rape Drugs, Business Journal (Milwaukee, Wis.), Nov. 12,
1999. The posters designed for Illinois were so well-received that other states, including Wisconsin and New Jersey, began using
them as well. Id.
244See GHB Jury Sends a Message: Convictions of 4 in Grosse Ile Date Rape Drug Death are First of Their Kind in Nation,
Detroit News, Mar. 15, 2000, at 1.
245See id.
246Krikorian, supra note 7.
43and sexual battery.247 Also in 1998, a Warren, Arkansas jury found Steven Sera, who used Rohypnol to
sexually assault and videotape several women, guilty of rape, sexual abuse, kidnapping, and introduction of
drugs and sentenced him to thirty years in prison.248 The APRI manual on drug-facilitated rape describes
several other convictions as well.249
Local governments have also sponsored public education campaigns about drug-facilitated rape. For instance,
immediately before college spring break of 2000, the Board of Supervisors of San Diego County and the
district attorney's oce spent $100,000 on billboards, bumper stickers, television and radio advertising,
posters and brochures, and announcements at a rock star concert.250 This campaign emphasized that young
women should protect each other from date-rape drugs and that men should realize that having sex with a
drunk women is rape.251 California's Santa Barbara County Sheri's Department, working with an alcohol
awareness group and local bars and restaurants, has developed a public education campaign called \Party
Smart." This campaign involves bar and restaurant owners hanging up posters about drug-facilitated rape
in women's restrooms and distributing lids for customers to place over their drinks.252
Thus during the 1990s, the federal, state, and local governments have each begun to respond to the problem
of drug-facilitated rape in a variety of dierent ways. The success of these responses is evaluated below after
a brief description of the non-governmental responses to the problem.
B. The Non-Governmental Response
247See McAllister, supra note 1; Brothers Sentenced in \Date-Rape" Drug Case, Los Angeles Times, July 7, 1998, at 4.
248Domingo Ramirez, Jr., Jury Finds Sera Guilty of Rape, Druggings, Fort Worth Star-Telegram, Mar. 15, 1998, at
1. Sera also pled guilty to drugging and raping a Texas woman, and was sentenced to fteen years to be served concurrently
with his thirty year Arkansas sentence. Domingo Ramirez, Jr., Rapist Takes Plea Deal in Colleyville Assault, Fort Worth
Star-Telegram, Aug. 14, 1999, at 1. One of Sera's victims won a verdict of one million dollars against Sera in a civil trial.
Domingo Ramirez, Jr., Victim of Rapist Awarded $1 Million, Fort Worth Star-Telegram, Dec. 17, 1998, at 1.
249APRI, supra note 12, at Ch. 4 (describing cases from Arkansas, California, Florida, Georgia, Louisiana, Massachusetts,
Michigan, Oklahoma, Pennsylvania, Virginia, and a federal case in Minnesota).
250Tony Perry, Ads Spread Date-Rape Drug Warning, L.A. Times, Apr. 2, 2000, at A24.
251See id.
252Tina Dirmann, Bars, Police Put Spotlight on Date-Rape Drug GHB, L.A. Times, Aug. 6, 2000, at B1.
44While the majority of the government's response has centered on pursuing legal changes and prosecuting
cases, rape crisis centers, victim advocacy organizations, and college campuses have focused on prevention,
education, and services for victims of drug-facilitated rapes. In August 1997, the Rape Treatment Center of
Santa Monica-UCLA Medical Center (RTC) launched a public awareness campaign introduced by Attorney
General Janet Reno.253 The campaign included distributing posters, iers, and bookmarks to colleges across
the country.254 As part of a Los Angeles County taskforce, the RTC, law enforcement ocials and the
County Medical Examiners oce developed procedures and a rape kit to improve evidence collection in
suspected drug-facilitated rape cases.255 The D.C. Rape Crisis Center (DCRCC) also developed a public
awareness campaign and created the Date Rape Drug Information Service, available at a toll-free number.256
Homann-La Roche provided the funding for this service, and worked closely with the DCRCC on developing
public education material.257 The Pennsylvania Coalition Against Rape commissioned a public service
announcement called \Rewind," which depicts, in reverse, a young woman waking up the morning after she
has been drugged in a bar and taken to an apartment where she is raped while unconscious.258 A search
of the Internet reveals a multitude of sites designed to educate about drug-facilitated rape and provide
assistance to its victims.259 As part of a series of books designed to educate adolescents about drug abuse,
the Drug Abuse Prevention Library published a book titled \Date Rape Drugs," explaining what date-rape
253Je Leeds, Reno Launches Drive Against `Date Rape Drugs,' L.A. Times, Aug. 12, 1997, at 1.
254Id.
255Fitzgerald and Riley, supra note 44, at 44.
256See NIJ, A Report to the Attorney General, supra note 15, at 40; DC Rape Crisis Center Seeks to Widen Focus on Date
Rape Drugs; Oers Assistance Through Toll-Free Information Line, PR Newswire, Oct. 4, 1999. See Substance Abuse &
Sexual Assault: When Drugs Are Used for Rape (visited Mar. 30, 2001) <http://www.dcrcc.org/drugs.html#1> to view the
DCRCC's approach to the issue of drug-facilitated rape.
257See DC Rape Crisis Center Seeks to Widen Focus on Date Rape Drugs, supra note 256.
258Reginald Oberlag, Provocative PSA Warns Women of Date Rape Drug, Shoot, Feb. 6, 1998, at 15.
259See, e.g., Date Rape Drugs (visited Apr. 8, 2001) <http://www.shs.unc.edu/library/alcohol.html>; Date Rape Drugs
(visited Apr. 8, 2001) <http://www.rsac-nip.org/daterapedrugs.html>; Protect Yourself Against Date-Rape Drugs (vis-
ited Apr. 8, 2001) <http://www.teenoutreachproject.com/TOP-Protect.html>; Date Rape Drugs (visited Apr. 8, 2000)
<http://www.watervillerape.org/drugs.html>.
45drugs are, how to prevent date rape, and what to do if someone is raped with drugs.260
Homann-La Roche has also made an eort to address the problem of drug-facilitated rape. Although the
manufacturer of Rohypnol has repeatedly emphasized that only a small number of drug-facilitated rape cases
involve Rohypnol, the company did make several changes involving the drug in particular. 261 In 1996, the
company decreased the number of Rohypnol distributors in Mexico from two hundred to sixteen and stopped
all manufacturing of the two milligram tablet.262 In 1997, the company developed a new formula of the drug
so that if the pill is placed in liquid it releases a blue dye.263 As mentioned above, Homann-La Roche
also has provided a free service for analyzing urine samples from suspected drug-facilitated rape victims,264
sponsored a public education campaign on drug-facilitated rape,265 and funded studies that attempt to
measure the prevalence of drug-facilitated rape.266 The eectiveness of these responses is discussed below.
III.
An Analysis of the Response to the Problem of Drug-Facilitated Rape and
Recommendations for Future Responses
Overall, the response to drug-facilitated rape has been impressive. The problem began emerging only a
decade ago, yet Congress has already passed two laws designed to address the problem, states have amended
260See Clare Tattersall, Date Rape Drugs (2000).
261One article describes Homann-La Roche's eorts as \pharmaceutical benecence," explaining, \Homan-LaRoche [sic]
could not aord to look like they were soft on rapists. With ironic intimacy, the Swiss-based conglomerate has matched and in
some cases, joined law enforcement, interdiction, victim services, and prosecutors in the battle against misuse of Rohypnol. At
the same time, it protested the singling out and demonizing of its cash cow." Welner and Delfs, supra note 49, at 7.
262See New International Threat of \Date-Rape Drug" Tracking (prepared statement of Robert B. Armstrong, Homann-La
Roche), supra note 34, at 44.
263Maker of Rohypnol Announces Color-Releasing Formulation, Alcoholism & Drug Abuse Week, Nov. 10, 1997, at 7.
264See Homan-La Roche Oers Law Enforcement Testing Capacity in Fight Against Rohypnol Misuse [sic], PR Newswire,
June 14, 1996; Mullins, supra note 116, at 966.
265See Homann-La Roche Emphasizes Strategy of Law Enforcement and Education to Deal with Rohypnol Misuse, PR
Newswire, June 17, 1996.
266See, e.g., Mullins, supra note 116 (analyzing urine samples collected from suspected drug-facilitated rape victims); Calhoun
et al., supra note 18 (summarizing Haight Ashbury Free Clinics' eld work and interviews of Rohypnol users in Texas).
46their controlled substances schedules and rape statutes, local governments have successfully prosecuted
several drug-facilitated rape cases, and all levels of the government as well as private actors have launched
education and prevention campaigns. These responses have occurred relatively quickly and have prompted
legislatures, other actors, and the public to continue thinking about the problem of drug-facilitated rape.
Unfortunately, these eorts have not eradicated the problem of drug-facilitated rape. Most likely some people
will always commit this crime, despite the best eorts of the government and other actors. More can be
done, however, to reduce its occurrence. Perhaps most importantly, legislators and educators must focus
on the general crime of drug-facilitated rape, rather than on solely the particular drugs used to commit the
crime. The story of Rohypnol demonstrates why a general focus is so essential. When Congress and the
states attached harsh penalties to the crime of distributing and possessing Rohypnol, the overall consensus
is that its use in general and as a date-rape drug decreased, but other drugs quickly replaced it as a rape
facilitator. 267 An advocate from the D.C. Rape Crisis Center testifying at the 1999 congressional hearing
explained:
I was a strong advocate of rescheduling Rohypnol, but I feel like we spent several years
focusing on that. Rohypnol is now fading from the scene. Other drugs are talking its place.
It is important that we not be sitting here 2 years from now talking about some other drug
and trying to gure out how to deal with it. We need to deal with the act and not the
specic vehicle.268
This advocate argues that \[b]y promoting the idea that these crimes involve only one or two substances, we
267See Date Rape Drugs (prepared statement of Hon. Fred Upton), supra note 110, at 3 (\Thanks to restrictions on its
import, federal controls, and changes the manufacturer made to make it less easy to abuse as a date rape drug, Rohypnol is
no longer a big part of the problem. Now, GHB, and to some extent, ketamine are the leading `date rape drugs."'); Controlled
and Uncontrolled Substances Used to Commit Date Rape (testimony of Michael Stevens), supra note 24, at 16 (describing
how after Florida increased penalties for Rohypnol tracking, Rohypnol sales dropped markedly and price increased, but then
\a new drug popped up and that was GHB... GHB right now is taking over the date rape drug moniker that rues did");
Telephone Interview with Sgt. Deborah Bjorndalen, Sex Crimes Supervisor, Broward County (Florida) Sheri's Oce (Apr.
5, 2001) (reporting that in Broward County Rohypnol-related rapes have decreased, while GHB- and Xanax-related rapes have
increased); Community Epidemiology Work Group, National Institute on Drug Abuse, Epidemiological Trends in Drug Abuse:
Advance Report (June 1999) (reporting that in Texas the BZ clonazapem (brand names Klonopin and Rivotril), which is used
to treat panic disorders, is replacing Rohypnol).
47are dangerously misleading women."269 Furthermore, \[a] focus on a particular drug creates the impression
that the drug itself is the problem, and can misdirect attention from the larger issues of sexual assault."270
The danger of focusing on particular drugs is thus two-fold; such a focus may mislead women into thinking
they are safe as long as they avoid certain drugs, and will most likely be ineective in stopping drug-facilitated
rape because other drugs will easily replace the targeted ones.
Congress seems to have recognized this danger, as it passed a law making it a crime to give a person any
drug to facilitate a crime of violence, but at times the legislative histories for the 1996 and 1999 acts and
the hearing transcripts read as if the issue is only about a particular drug { namely Rohypnol or GHB. The
scheduling of GHB and ketamine and the increased penalties for Rohypnol will indeed most likely eventu-
ally decrease these drugs' role in drug-facilitated rape. However, during the three years it took the federal
government to schedule GHB, both Congress and the responsible executive agencies might have been too
involved in the ght over the appropriate scheduling level, and not involved enough in devising other ways
to deal with the problem of sexual assault. Two commentators have concluded that \[s]cheduling changes
pale in importance to the public education, education of law enforcement about the appropriate response
to suspected substance facilitated sexual assault,... [and] restriction of the distribution network."271 Yet
despite the general recognition of the importance of education, the bulk of hearing testimony and Congres-
sional debate centered not on how to better educate the public or law enforcement, but on how to schedule
Rohypnol, GHB, and ketamine.
In analyzing the federal government's scheduling actions with respect to these three drugs, it is useful to
compare the huge debates surrounding GHB and Rohypnol scheduling with the almost nonexistent dispute
regarding the scheduling of ketamine. Homan-LaRoche and Orphan Medical lobbied against the place-
269DC Rape Crisis Center Seeks to Widen Focus on Date Rape Drugs, supra note 256.
270Calhoun, supra note 18, at 189.
271Welner and Delfs, supra note 49, at 10.
48ment of their drugs in schedule I,272 while the major manufacturers of ketamine supported the placement
of ketamine in schedule III. The ease with which ketamine was scheduled suggests that the position and
lobbying power of the pharmaceutical industry greatly aects scheduling outcomes. This phenomenon may
seem positive or negative, depending on one's outlook on the motives of pharmaceutical companies. In the
case of GHB, Orphan Medical's lobbying appears to have had a good eect on the scheduling process because
it managed to keep the drug available for the narcoleptics who so desperately need it. Contributing to this
positive assessment of Orphan Medical's actions are the facts that no other treatment has shown as much
promise for narcoleptics and Orphan Medical was willing to develop the drug, at FDA's urging, when larger
pharmaceutical companies would not because it would not be protable.
In contrast, Homann-LaRoche's lobbying seems less benecial, because the company appears more con-
cerned with its prots than with the safety of women. As a Florida lieutenant stated, the company does
not want to lose its \cash cow," even though \there are very suitable alternative sleeping aids that do not
have the same devastating eects as Rohypnol."273 Given that the company never sought approval for the
drug in the U.S, one might wonder why Homann-LaRoche was adamantly opposed to the U.S. placing
Rohypnol in a category stating that the drug has a high potential for abuse and no legitimate medical use in
this country, and yet at the same time advocated for harsher penalties for those who misuse Rohypnol. The
inescapable explanation for these apparently conicting positions is that Homann-LaRoche believed a U.S.
scheduling increase would be the \kiss of death" internationally for the company's most protable drug.274
Even though the extent of Rohypnol-related rapes is unknown, the government should always err on the
side of over-protection when the only loser is a multi-million dollar pharmaceutical company (as opposed to
272See supra note 161 (noting that Homann-LaRoche spent $130,000 on outside lobbying eorts that mainly focused on
Rohypnol during a six month period); Barshay, supra note 72 (stating that Orphan Medical marketing director spent eighty
percent of her time in 1999-2000 lobbying).
273Telephone Interview with Lt. David Robshaw, Broward County (Fla.) Sheri's Oce (Apr. 5, 2001). See also New
International Threat of \Date-Rape Drug" Tracking (prepared statement of Terrance W. Woodworth,) supra note 34, at 24
(stating that there are no medical indications for which Rohypnol is the only choice of treatment and that many other drugs
are available as eective insomnia treatments and preanesthetics).
274See Welner and Delfs, supra note 49, at 5 { 6, 8.
49a group of patients who greatly need a particular drug).275 Congress or the Attorney General should have
placed Rohypnol in schedule I when it had the chance in 1996, and should still do so today. Now that other
drugs have begun to replace it, however, the need for rescheduling does not seem as pressing as in 1996,
especially because the states with the largest Rohypnol problems have passed their own laws rescheduling
the drug or increasing the penalties associated with it.276
Although I am critical of Homann-LaRoche's opposition to rescheduling Rohypnol, it must be noted that
the company did implement several changes in response to the perception that its drug was being used to
rape women, as noted above.277 The large-scale restriction of points of distribution in Mexico surely has
helped to stem the availability of Rohypnol in the U.S.278 Law enforcement ocials are somewhat more
skeptical about the eectiveness of the reformulation of the drug so that it releases a blue dye when dis-
solved. One detective told Congress, \I can attest to my experience in nightclubs that a blue dye... is not
going to have any eect in a night club. It is not well lit in a night club. Nobody is checking their [sic]
Jack Daniels and Coke for blue dye."279 In addition to diculty viewing the dye in dimly lit places or in
such dark drinks as red wine or soda, it takes twenty-minutes for a drink to turn blue.280 Other skeptics
of the company's actions point to its national urinalysis program that was designed to collect scientically
valid data to determine which drugs are used to facilitate rape. As mentioned above, the design of the study
precludes a reliable answer to this question.281 Homann-LaRoche, however, widely publicized the results
showing that Rohypnol was used in only a miniscule amount of cases, without any acknowledgement of the
275Perhaps this is an unfair comparison, but in my mind on one side of the scale sits the years of anguish a rape victim
experiences while on the other side is a decrease in a Homann-LaRoche shareholder's stock values.
276See Florida and Texas laws, listed in Table I in the appendix.
277See notes 261 { 66 and accompanying text.
278See Welner and Delfs, supra note 49, at 10.
279Controlled and Uncontrolled Substances Used to Commit Date Rape (testimony of Michael Stevens), supra note 24, at 44;
see also Controlled and Uncontrolled Substances Used to Commit Date Rape (prepared statement of John H. King), supra note
24, at 52.
280NIJ, A Report to the Attorney General, supra note 15, at 39.
281See notes 115 { 21 and accompanying text.
50limitations of the study.282 Moreover, some law enforcement ocials found the company's eorts to become
involved in the criminal justice system's handling of Rohypnol-facilitated rape cases as \heavy-handed and
threatening."283 The DOJ Drug-Facilitated Rape Working Group concluded that the company's actions are
\both an attempt by the manufacturers to keep their drug (and other drugs) from being used for sexual
assault, and... an eort to protect the market viability of their product by producing information that would
challenge the eort to reschedule the drug to Schedule I."284 Other commentators have looked less favorably
upon the company's attempts \to play do-goodnick" and have attributed these eorts solely to concern about
not losing prots as a result of a scheduling change or potential legal liability in negligence suits from victims
of Rohypnol-related rape cases.285 If Homann-LaRoche is truly concerned about the problem of sexual
assault, it should not oppose any further attempts to reschedule the drug, and it could provide additional
funding for prevention campaigns and better-designed research studies, such as those suggested by the DOJ's
Drug-Facilitated Rape Working Group.286
One promising response to the problem of drug-facilitated rape is the 1996 law that Congress passed which
makes it a crime punishable by up to twenty years in prison to administer a controlled substance to a victim
with the intent to commit a crime of violence upon that person. This law does exactly what rape crisis
centers and others have advocated, in that it focuses on the act of drug-facilitated sexual assault, not a
particular drug. Prosecutors appear, however, to have rarely used the federal law.287 One commentator
282NIJ, A Report to the Attorney General, supra note 15, at 39.
283Id. at 39 { 40.
284Id. at 39.
285Welner and Delfs, supra note 49, at 10 (suggesting that the deep pockets of a pharmaceutical company would lead a rape
victim to sue Homann-LaRoche instead of her rapist in a negligence suit).
286See NIJ, A Report to the Attorney General, supra note 15, at 47 { 49 (suggesting a major, multi-year research initiative
consisting of four parts: (1) measuring the incidence of drug-facilitated rap among suspected cases; (2) measuring the incidence
of drug-facilitated rape in the population; (3) measure the incidence of drug-facilitated rape among high risk populations; and
(4) study drug-facilitated rape in the context of acquaintance rape).
287In fact, after an extensive search of media databases and case law, I could nd only one case in which the law has been used.
51oers a plausible explanation for the infrequent use of this law: \It is not likely that the FBI, DEA, and
federal judiciary will have the resources to pursue each individual `date rape' case." 288 A local law
enforcement ocial believes that the law is almost never used because states do not \like having the feds
involved in their prosecutions."289 But limited resources and territoriality concerns should not stop the state
and federal governments from working together to send the tough message the law was intended to convey:
\[u]se controlled substances to commit a crime, and you will do federal time."290 More prosecutions need to
occur under this law to deter and punish potential date-rape druggists.
Furthermore, every state should enact a law that attaches long sentences to the crime of using a drug to
sexually assault a victim. The Massachusetts statute serves as a good model for this type of law. It states:
Whoever applies, administers to or causes to be taken by a person any drug, matter or thing
with intent to stupefy or overpower such person so as to thereby enable any person to have
sexual intercourse or unnatural sexual intercourse with such person shall be punished by
imprisonment in the state prison for like or for any term of years not less than ten years.291
Many states have amended their denitions of sexual assault or consent to cover drug-facilitated rape, but
the Massachusetts law is an even better approach because it does not require that an actual rape take place,
but rather requires only that the perpetrator intended to rape a victim he drugged. As local prosecutors are
responsible for the great majority of rape cases, state laws will have the greatest deterrent eect on potential
perpetrators and will be used most often to punish rapists who drug their victims.
In March 1999, Peter Allan, Sr. was indicted in the federal District of Minnesota under the Drug Induced Rape Prevention and
Punishment Act for using the sleeping drug Ambien to rape a fteen-year-old girl and a fty-one-year-old woman. See United
States Attorney District of Minnesota, News Release (Mar. 1, 1999), available in APRI, supra note 12. In February 2000, he
was convicted and sentenced to nine years in prison. Had the case been prosecuted under Minnesota state law, Allan would
have received a sentence ranging from ve to eight years, with only two-thirds of the sentence having to be served in prison.
James Walsh, Authorities Hope 9-Year Sentence Sends Message on Date-Rape Drug, Star Tribune (Minneapolis, Minn.), Feb.
25, 2000, at 1B. Prosecutors reported that this was the rst conviction under the 1996 act. Id.
288George B. Stevenson, Federal Antiviolence and Abuse Legislation: Toward Elimination of Disparate Justice for Women and
Children, 33 Willamette L. Rev. 848, 861 (1997). See also Telephone Interview with Marcia Lee, supra note 147 (explaining
that the federal law has been used so infrequently because most rape prosecutions occur at the local level).
289Telephone Interview with Lt. David Robshaw, supra note 273.
290Walsh, supra note 287.
52Despite the legal focus of this paper, the most eective response to the problem of drug-facilitated rape is
public education. Public education campaigns must have two goals. One goal must be to teach potential
drug-rapists that it is not acceptable to use drugs to make it easier to get consent from a victim or to
overpower a victim, while the other must be to educate potential victims on how to prevent becoming a
drug-facilitated rape victim. Although teaching people how to keep themselves from becoming victims may
seem easier than teaching people that drug-facilitated rape is wrong, both goals must receive attention in
order to eectively reduce the prevalence of this crime.292 As a National Organization for Women repre-
sentative explained, \Men are taught that it's OK to `get it' any way they can. That's the mindset we
have to change."293 Such organizations such as Men Can Stop Rape use education programs in high schools
to teach men not to rape.294 Information about drug-facilitated rape should be included in these types of
educational campaigns targeted at men. The San Diego prevention campaign, described above,295 included
an advertisement aimed at convincing men that having sex with a drunk or unconscious women is rape, as
well as two other advertisements aimed at teaching friends to protect each other from would-be rapists.296
The Hillory J. Farias and Samantha Reid Date-Rape Drug Prohibition Act of 1999, although mostly focused
on GHB, takes a step in the right direction by ordering the Secretary of DHHS and Attorney General to
develop a national awareness campaign. The campaign must include information on the danger of date-rape
drugs, the applicability of the Controlled Substances Act to these drugs, including penalties, how to recog-
nize symptoms indicating that a person may be a victim of such drugs, and how to respond to a person who
has been given such drugs.297 The campaign must target youth, young adults, law enforcement personnel,
292It is also important not to place responsibility for preventing this crime solely on victims, as this country has tended to do
so often when thinking about rape.
293Perry, supra note 250, quoting Mary Susan Sterner.
294See www.mencanstoprape.org (visited Apr. 16, 2001).
295See notes 250 { 51 and accompanying text.
296Perry, supra note 250. In one of the advertisements, Shannon MacMillan, a member of the U.S. soccer team that won the
1999 Women's World Cup, says, \If a friend has too much to drink or can't take care of herself, help her, before somebody
hurts her." Id.
297Hillory J. Farias and Samantha Reid Date-Rape Drug Prohibition Act of 1999, Pub. L. 106-172, 114 Stat. 7 (codied in
scattered sections of 21 U.S.C.) (June 2000 Supp.).
53educators, school nurses, rape counselors, and hospital emergency department sta.298 This federal aware-
ness eort, as well as the campaigns of state and local government, should continue until the prevalence of
drug-facilitated rape greatly decreases.
In addition to governmental awareness campaigns, fraternity organizations, bars, and clubs should also take
responsibility for educating the people who frequent their locations. These organizations can easily hang
posters warning of drug-facilitated rape in their restrooms, hand out awareness cards and oer lids to place
over one's drink to prevent someone from slipping a drug into it.299 Some commentators have even suggested
imposing third party liability on places that are \hotbeds for rape drug use," arguing that \[e]xpanding re-
sponsibility to the actor and the environments that breed this culture may prove more eective" than eorts
to change the formulation of Rohypnol pills.300 A law enforcement ocial in Florida similarly suggests that
because certain bars \are far more prone to have date rape drug problems, we could perhaps have some
type of sanction for bars that have a high percentage of these cases."301 Third party liability or sanctions,
although attractive, would most likely fail a legal challenge. The idea, however, illustrates the importance
of involving bars and fraternities in the solution to the problem.
Finally, all levels of the government must focus on training law enforcement ocials and prosecutors to deal
with the crime of drug-facilitated rape. One law enforcement ocer believes that one of the most important
actions the government can take to deal with the problem of drug-facilitated rape is to \train ocers to
be open to the possibility of drug-facilitated rape and to not re-victimize the victim."302 A Senate sta
member similarly reports that the \big piece the federal government is doing and needs to continue doing is
the training of local law enforcement about date-rape drugs."303 The Attorney General's collaboration with
298Id.
299The \Party Smart" campaign in Santa Barbara County, California involves each of these actions. Dirmann, supra note
252.
300Welner and Delfs, supra note 49, at 10.
301Telephone Interview with Lt. James Stormes, Head of Special Investigation, Palm Beach County Sheri's Oce (Apr. 6,
2001).
302Telephone Interview with Lt. James Stormes, supra note 301.
303Telephone Interview with Marcia Lee, supra note 147.
54the APRI to produce a video and training manual on drug-facilitated rape for prosecutors serves as a good
model for cooperation between the federal government and a private organization to create an educational
tool that can be used by local prosecutors.304 Similar initiatives should be undertaken by additional groups.
The DEA, with the help of the Federal Bureau of Investigation, is currently fullling its responsibility under
the 1999 federal law to develop model protocols, training materials, forensic eld tests, and coordination
mechanisms for investigations and prosecutions relating to date-rape drugs.305 Hopefully these tools will
help decrease the number of drug-facilitated rapes that occur in this country.
IV. Conclusion
Drug-facilitated rape emerged in the 1990s as a troubling new crime aecting an unknown
number of girls and women. This paper has explained the ways in which drug-facilitated rape
diers from other forms of rape and described the three drugs believed to be most commonly
used to facilitate rape. It has examined the federal, state, local, and private responses to
Rohypnol, GHB, ketamine, and the crime of drug-facilitated rape. The response has focused
on changing criminal and drug control law, educating the public and law enforcement about
drug-facilitated rape, and creating prevention strategies. These initiatives are a step in the
right direction, but much more most be done to eectively curb drug-facilitated rape. This
paper has provided some recommendations for additional responses, emphasizing the need to
focus on the general crime of drug-facilitated rape rather than specic drugs. Above all, when
strategizing about and discussing this problem, we must remember to take into account the
views of the victims of this horric crime. As one commentator warns, \We are missing a
304See supra note 173 and accompanying text.
305Telephone Interview with Marcia Lee, supra note 147.
55clear understanding of the exploited and how they view experiences that have captured the
imagination and outrage of so many. The heart of the problem beats far from our state capitals
and television stations."306 Any future responses must heed this warning and pay attention to
the perspective of the victims of drug-facilitated rape.
APPENDIX
Table I: State Control of Rohypnol, GHB, and Ketamine
(as of April 1, 2001)
Rohypnol GHB IV. Ketamine
Ala. V.
Sch.
IV
Ala.
Ad-
min.
Code
r.
420-
7-
2
(2000)
VI.
Sch.
I
VII.
Ala.
Ad-
min.
Code
r.
420-
7-
2
VIII.
(2000)
IX.
Sch.
III
Ala.
Ad-
min.
Code
r.
420-
7-
2
(2000)
Alaska X. Sch. IV-A
Alaska Stat. x 11.71.170
(2000)
XI. Sch.
IV-A
Alaska Stat. x
11.71.170
(2000)
XII. Sch. IV-A
Alaska Stat. x
11.71.170 (2000)
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56Ariz. XIII.
Sch.
IV
Ariz.
Rev.
Stat.
x
36-
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(1998)
XIV.
Sch.
I
Ariz.
Rev.
Stat.
x
36-
2512
(2000)
XV.
Sch.
IV
Ariz.
Rev.
Stat.
x
36-
2514
(2000)
Ark. XVI. Sch. IV
Weil's Code of Ark. Rules
& Reg.
007 07 CARR 002 (2001)
XVII. Sch.
I
2001 Ark. Adv.
Legis. Serv.
320 (Michie),
amending Ark.
Code Ann.
x 5-64-215
XVIII. Sch. III
Weil's Code of Ark.
Rules & Reg.
007 07 CARR 002
(2001)
Cal. XIX.
Sch.
IV
Cal.
Health
&
Safety
Code
x11057
(2001)
XX.
Sch.
II
Cal.
Health
&
Safety
Code
x11055
(2001)
XXI.
Sch.
III++
Cal.
Health
&
Safety
Code
x11056
(2001)
Colo. XXII. Sch. IV
Col. Rev. Stat. x 18-18-206
(2000)
+ XXIII. Sch. III
Col. Rev. Stat. x
18-18-205
(2000)
Conn. XXIV. Sch. IV
Conn. Agencies Regs. x
21a-243-10 (1999)
XXV. Sch.
I
XXVI. Conn.
Agencies Regs.
x 21a-243-7
(1999)
XXVII. Sch. IV
Conn. Agencies Regs.
x 21a-243-9 (1999)
Del. XXVIII. Sch. IV
Del. Code Ann. tit. 16, x
4720 (2000)
XXIX. Sch.
I
Del. Code Ann.
tit. 16, x 4714
(2000)
Sch. III
Del. Code Ann. tit.
16, x 4718
(2000)
57Fla. XXX. Sch. I++
Fla. Stat. ch. 893.03
(1997)
XXXI. Sch.
II++
Fla. Stat. ch.
893.03 (1997)
XXXII. Sch. III
Fla. Stat. ch. 893.03
(1997)
Ga. XXXIII. Sch. IV++
Ga. Code Ann. x16-13-28
(2000)
XXXIV.
Sch. I
Ga. Code Ann.
x16-13-25
(1999)
Sch. III
Ga. Code Ann.
x16-13-27 (2000)
Haw. XXXV. Sch. IV
Haw. Rev. Stat. x 329-20
(2000)
XXXVI.
Sch. I
Haw. Rev.
Stat. x 329-14
(2000)
Sch. III
Haw. Rev. Stat. x
329-18 (2000)
Idaho XXXVII. Sch. I
Idaho Code x 37-2705
(2000)
XXXVIII.
Sch. I
Idaho Code x
37-2705 (2000)
XXXIX. Sch. III
Idaho Code x 37-2709
(2000)
Ill. XL. Sch. IV
720 Ill. Comp. Stat.
570/210 (2000)
XLI. Sch. 1
720 Ill. Comp.
Stat. 570/204
(2000)
Sch. III
720 Ill. Comp. Stat.
570/208
(2000)
Ind. XLII. Sch. IV
Ind. Code x 35-48-2-10
(2000)
XLIII. Sch.
II
Ind. Code x
35-48-2-6
(2000)
Sch. III
Ind. Code x 35-48-2-8
(2000)
Iowa Sch. IV
Iowa Code x 124.210 (2000)
XLIV. Sch.
I++657 Iowa
Admin. Code r.
657-10.20(124)
(2001)
Sch. IV
Iowa Code x 124.208
(2001)
Kan. Sch. IV
Kan. Stat. Ann. x 65-4111
(1999)
Sch. IV
Kan. Stat.
Ann. x 65-4111
(1999)
Sch. III
2000 Kan. Sess. Laws
108, amending
Kan. Stat. Ann. x
65-4109
58Ky. XLV. Sch. IV
902 Ky. Admin. Regs.
55:030 (1999)
XLVI. Sch.
I
Ky. Rev. Stat.
Ann. x
218A.050
(Banks-
Baldwin
2001)
XLVII. Sch. IV
902 Ky. Admin. Regs.
55:025
(1999)
La. Sch. IV
La. Rev. Stat. Ann.
x40:964 (West 2000)
Sch. II+
La. Rev. Stat.
x40:964 (2000)
Sch. III
La. Rev. Stat. x40:964
(2000)
Me. XLVIII. Sch. W307
Me. Rev. Stat. Ann. tit.
17-A, x 1102 (2000)
Md. Sch. IV
Md. Ann. Code art. 27,
x279 (2001)
Sch. III
Md. Ann. Code art.
27, x279 (2001)
Mass. Class A308
Mass. Gen. Laws Ann. ch.
94C, x31 (2001)
Class A
Mass. Gen.
Laws Ann. ch.
94C, x31 (2001)
XLIX. Class A
L. Mass. Gen.
Laws Ann. ch. 94C,
x31 (2001)
Mich. Sch. IV
Mich. Comp. Laws
x333.7218 (2000)
Sch. I
Mich. Comp.
Laws x333.7212
(2000)
Sch. III
Mich. Comp. Laws
x333.7216
(2000)
Minn. Sch. I
Minn. Stat. x152.02 (2000)
LI. Sch. III
Minn. Stat.
x152.02 (2000)
Miss. Sch. IV
Miss. Code Ann. x
41-29-119 (2001)
Sch. I
2001 Miss. S.
B. 2213,
amending Miss.
Code Ann. x
41-29-113
(2001)
Sch. III
Miss. Code Ann. x
41-29-117
(2001)
Mo. Sch. IV
Mo. Rev. Stat. x 195.017
(1999)
LII. Sch. IV
Mo. Rev. Stat. x
195.017 (1999)
Mont. Sch. IV
Mont. Code Ann. x
50-32-229 (2000)
307Maine has four schedules of controlled substances, W through Z, with W as the highest schedule.
308Massachusetts has ve classes of controlled substances, A through E, with A as the highest class.
59Neb. Sch. IV
Neb. Rev. Stat. x 28-405
(2000)
Sch. I
Neb. Rev.
Stat. x 28-405
(2000)
Sch. III
Neb. Rev. Stat. x
28-405 (2000)
Nev. Sch. IV++Nev. Admin.
Code x 453.540 (2001)
Sch. I++
Nev. Admin.
Code x 453.510
(2001)
Sch. I
Nev. Admin. Code x
453.510
(2001)
N.H. Sch. I++
N.H. Rev. Stat. Ann.
x318-B: 1-C (2000)
Sch. II
N.H. Rev. Stat.
Ann. x318-B:
1-C (2000)
LIII. Sch. III
N.H. Rev. Stat. Ann.
x318-B: 1-C (2000)
N.J. Sch. IV++
N.J. Admin. Code tit. 8,
x65-10.4 (1989)
+ Sch. III
N.J. Stat. Ann. x 24:
21-7
(West 2001)
N.M. Sch. I
16 N.M. Admin. Code tit.
16,
x 19.20.28 (2000)
Sch. I
16 N.M.
Admin. Code
tit. 16,
x 19.20.28
(2000)
Sch. III
16 N.M. Admin. Code
tit. 16,
x 19.20.28 (2000)
N.Y. LIV. Sch. IV
N.Y. Pub. Health Law x
3306 (Consol. 2001)
LV. Sch. I
N.Y. Pub.
Health Law x
3306
(Consol. 2001)
LVI. Sch. III
N.Y. Pub. Health Law
x 3306 (Consol. 2001)
N.C. LVII. Sch. IV
N.C. Gen. Stat. x 90-92
(2000)
LVIII. Sch.
I
N.C. Gen. Stat.
x 90-89 (2000)
LIX. Sch. III
N.C. Gen. Stat. x
90-91 (2000)
N.D. Sch. I++
N.D. Cent. Code x
19-03.1-05 (2000)
Sch.
I++2001 N.D.
H.B. 1096,
amending N.D.
Cent. Code x
19-03.1-05
Sch. III
2001 N.D. H.B. 1096,
amending N.D. Cent.
Code x 19-03.1-09
(2000)
Ohio Sch. IV
Ohio Rev. Code Ann.
x3719.41 (Anderson 2000)
Sch. I
Ohio Rev.
Code Ann.
x3719.41
(Anderson
2000)
Sch. III
Ohio Rev. Code Ann.
x3719.41 (Anderson
2000)
60Okla. Sch. I
Okla. Stat. tit. 63, x2-204
(2000)
Sch. I
Okla. Stat. tit.
63, x2-204
(2000)
Sch. III
Okla. Stat. tit. 63,
x2-208 (2000)
Or. LX. Sch. IV
Or. Admin. R.
855-080-0024 (2000)
LXI. Sch.
I
Or. Admin. R.
855-080-0021
(2000)
LXII. Sch. III
Or. Admin. R.
855-080-0023
(2000)
Pa. Sch. I
28 Pa. Code x25.72
(2001)
Sch. I
35 Pa. Cons.
Stat. Ann. x
780-104 (2000)
Sch. III
35 Pa. Cons. Stat.
Ann. x 780-104 (2000)
R.I. Sch. IV
R.I. Gen. Laws x
21-28-2.08 (2001)
Sch. I
R.I. Gen. Laws
x 21-28-2.08
(2001)
Sch. III
R.I. Gen. Laws x
21-28-2.08 (2001)
S.C. Sch. IV+
S.C. Code Ann. x
44-53-250
(Law Co-op. 2000)
Sch. IV+
S.C. Code Ann.
x 44-53-190
(Law Co-op.
2000)
S.D. LXIII. Sch. IV++
S.D. Codied laws x
34-20B-25 (2000)
LXIV. Sch.
III
S.D. Codied
laws x
34-20B-20
(2000)
LXV. Sch. III
S.D. Codied laws x
34-20B-22 (2000)
Tenn. Sch. IV++
Tenn. Code Ann.
x39-17-412 (2000)
Sch. IV
Tenn. Code
Ann.
x39-17-412
(2000)
Sch. III
LXVI. Tenn.
Code Ann.
x39-17-410
LXVII. (2000)
Tex. LXVIII. Sch. IV++
26 Tex. Reg. 795 (2001)
LXIX. Sch.
I
26 Tex. Reg.
795 (2001)
LXX. Sch. III
26 Tex. Reg. 795
(2001)
Utah LXXI. Sch. IV
Utah Code Ann. x 58-37-4
(2000)
LXXII. Sch.
I
Utah Code
Ann. x 58-37-4
(2000)
LXXIII. Sch. III
Utah Code Ann. x
58-37-4 (2000)
61Vt. LXXIV. Regulated
Drug309
Vt. Code R. 13-140
011 (1998)
Va. Sch. IV+
Va. Code Ann. x 54.1-3452
(Michie 2000)
Sch. IV+
Va. Code Ann.
x 54.1-3446
(Michie 2000)
Sch. III
Va. Code Ann. x
54.1-3450
(Michie 2000)
Wash. LXXV. Sch. IV++
Wash. Rev. Code x
69.50.210 (2001)
LXXVI.
Sch. I
2000-17 Wash.
St. Reg. 015
(2000)
LXXVII. Sch. III
Wash. Admin. Code x
24-887-160 (2000)
W.
Va.
Sch. IV
W.Va. Code x 60A-2-210
(2000)
Wis. LXXVIII. Sch. I++
Wis. Stat. x 961.20 (2000)
LXXIX.
Sch. I++
Wis. Stat. x
961.14 (2000)
Sch. III++Wis. Stat.
x 961.18 (2000)
Wyo. Sch. IV
Wyo. Stat. x 35-7-1020
(2000)
LXXX. Sch.
I
2001 Wyo.
H.B. 129,
amending Wyo.
Stat. x
35-7-1014
LXXXI. Sch. III
2001 Wyo. H.B. 129,
amending Wyo. Stat. x
35-7-1018
 denotes states that have placed GHB in schedule I, with the exception that any FDA-approved GHB will
be added to schedule III (mirroring the federal scheme devised in the Hillory J. Farias and Samantha Reid
Date-Rape Drug Prohibition Act of 1999).
+ denotes states that have created special crimes and/or penalties fro tracking in or possessing Rohypnol,
GHB, or ketamine, either in addition to or instead of scheduling these drugs.
# denotes scheduling decisions made pursuant to the provision of the Uniform Controlled Substances Act that
requires the automatic scheduling or increase in schedule when the federal government controls or changes
the schedule of a drug. Because the federal laws scheduling GHB and ketamine are so recent, some states
have not yet amended their ocial schedules to list GHB and ketamine. Conversations with representatives
of several boards of pharmacy and other state agencies informed me that even if GHB or ketamine is not
found in the ocial schedule list available on Westlaw or Lexis, a state following this provision of the Uniform
Controlled Substances Act still considers GHB or ketamine to be a schedule I or III drug, respectively. Some
309Vermont does not have separate schedules or classes of drugs. Instead, it groups all controlled drugs together under the
title \Regulated Drugs."
62states are simply waiting for the next printing of their schedules. For this reason, no statutory or regulatory
authority is listed for these states, unless the drug specically appears in a schedule.310
310If a statute or regulation already specically listed GHB or ketamine in schedule I or III, respectively, I did not research
whether this occurred pursuant to the Uniform Controlled Substances Act only after the federal scheduling of these drugs or
whether states had already placed these drugs into these schedules before the federal government did so. Thus some states
may not be marked with an \#" even though they did indeed adopt these schedules only after the federal government did so
pursuant to the Uniform Controlled Substances Act.
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